Category: FDA Approvals

This category focuses on FDA approvals for drugs, biologics, and devices. Here you will find clear summaries of each decision, the data behind it, and the clinical context that helps make sense of what the approval means in real world care.

Enhertu Is Now FDA-Approved for HER2-Positive Early Breast Cancer Before and After Surgery. Here Is What the DESTINY-Breast11 and DESTINY-Breast05 Data Shows.

✅ Updated May 19, 2026: FDA Approval Confirmed On May 15, 2026, the FDA approved two new indications for Enhertu (fam-trastuzumab deruxtecan-nxki, T-DXd) in adults with HER2-positive early-stage breast cancer. This post has been updated throughout to reflect both approvals. For related coverage of Enhertu’s approved indications in metastatic HER2-positive and HER2-low breast cancer, and how this new approval extends Enhertu into the curative-intent setting, see our companion post on Dato-DXd in triple-negative breast cancer for context on the broader ADC landscape.

📌 The essentials: Two approvals, two different clinical situations Indication 1: Neoadjuvant (before surgery) FDA approved Enhertu followed by THP (taxane, trastuzumab, pertuzumab) for adults with HER2-positive (IHC 3+ or ISH+) stage II or III breast cancer before surgery. Dose: 5.4 mg/kg IV every 3 weeks for 4 cycles, then THP for 4 cycles, then surgery. Clinical basis: DESTINY-Breast11 (NCT05113251): pCR rate 67.3% with T-DXd plus THP versus 56.3% with standard anthracycline-based ddAC-THP (absolute improvement +11.2%; p=0.003). Indication 2: Adjuvant (after surgery, for residual disease) FDA approved Enhertu for adults with HER2-positive (IHC 3+ or ISH+) breast cancer who have residual invasive disease after neoadjuvant HER2-targeted treatment. Dose: 5.4 mg/kg IV every 3 weeks for a maximum of 14 cycles. Clinical basis: DESTINY-Breast05 (NCT04622319): T-DXd reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 (Kadcyla) (HR 0.47; 95% CI 0.34 to 0.66; p less than 0.0001). Three-year invasive disease-free survival (iDFS): 92.4% versus 83.7%. Key safety note: the label carries a boxed warning for interstitial lung disease (ILD) and pneumonitis. ILD rate was 4.4% in DESTINY-Breast11 and approximately 10% in DESTINY-Breast05. Additional warnings: neutropenia and left ventricular dysfunction.

When a woman is diagnosed with HER2-positive breast cancer, the weeks between diagnosis and surgery are not a waiting period. They are a treatment window, one that oncologists have spent decades trying to use more aggressively and more effectively. The drugs given before surgery, in the neoadjuvant setting, have the opportunity to shrink the tumor, treat any cancer that may have spread to lymph nodes or beyond, and ideally produce an outcome that changes what surgery looks like and what long-term prognosis looks like.

That neoadjuvant window has been anchored to anthracycline-containing chemotherapy regimens for more than a decade. Anthracyclines work, but they carry a burden: cardiac toxicity, hematologic toxicity, significant treatment interruptions. The question oncologists have been asking is whether something better is now available.

On May 18, 2026, the FDA is expected to rule on exactly that question. The drug at the center of the decision is Enhertu (trastuzumab deruxtecan, T-DXd), an antibody-drug conjugate that has already redefined outcomes in metastatic breast cancer. The clinical trial behind the application, DESTINY-Breast11, is the first positive global registrational trial for a new neoadjuvant agent in HER2-positive early breast cancer in over a decade. The data makes a compelling case. Understanding what it actually shows, and what it doesn’t yet tell us, is what this post is for.

HER2-Positive Breast Cancer and the Neoadjuvant Treatment Window

HER2 (human epidermal growth factor receptor 2) is a protein that promotes cell growth. In approximately 15 to 20% of breast cancers, the HER2 gene is amplified, producing too many HER2 receptors on tumor cell surfaces and driving aggressive cancer growth. HER2-positive breast cancer tends to grow faster than hormone receptor-positive cancer but is also more sensitive to HER2-targeted therapies.

Neoadjuvant therapy refers to systemic treatment given before surgery. This is different from adjuvant therapy, which is given after surgery to reduce recurrence risk. In HER2-positive early breast cancer, neoadjuvant treatment serves several purposes:

It may downstage the tumor, reducing its size and lymph node involvement, potentially enabling less extensive surgery
It allows oncologists to observe the tumor’s response to treatment in real time
It provides important prognostic information that guides post-surgery treatment decisions
Most critically: it creates the opportunity for pathologic complete response, the most meaningful outcome measure in this setting

What is a pathologic complete response (pCR) and why does it matter? A pathologic complete response (pCR) means that when the removed tumor and lymph nodes are examined under a microscope after surgery, no viable invasive cancer cells are found. In DESTINY-Breast11, the pCR definition used was ypT0/is ypN0, meaning no residual invasive cancer in the breast (with allowance for non-invasive in-situ disease) and no cancer in the lymph nodes. pCR is one of the most important prognostic markers in HER2-positive breast cancer. Patients who achieve pCR have substantially lower rates of cancer recurrence and significantly better long-term survival than those with residual disease. The relationship between pCR and survival is why the FDA accepts it as a surrogate endpoint for approval in the neoadjuvant setting. The clinical decision implications extend beyond prognosis. Patients who achieve pCR typically continue with standard adjuvant therapy and may be candidates for less extensive surgery. Patients who do NOT achieve pCR are typically offered additional targeted therapy after surgery (currently, T-DM1/Kadcyla is the standard for residual HER2+ disease) to try to reduce their recurrence risk. Understanding pCR rates is therefore both a survival question and a treatment-planning question.

What Enhertu Is and How It Works

Enhertu (trastuzumab deruxtecan, T-DXd) is an antibody-drug conjugate (ADC), a category of targeted therapy that links a cancer-targeting antibody to a chemotherapy payload. The antibody component is trastuzumab, which has been a cornerstone of HER2-positive breast cancer treatment for decades. The payload is deruxtecan, a topoisomerase I inhibitor chemotherapy. The linker between them is designed to be stable in the bloodstream but cleaved inside tumor cells.

The mechanism creates a guided delivery system. Trastuzumab finds tumor cells expressing HER2 on their surface and binds to them. The ADC is then internalized into the cell, where the linker is cleaved and the deruxtecan payload is released directly inside the cancer cell, causing it to die. A key additional property of T-DXd’s payload is what’s called a bystander effect: some of the released chemotherapy can diffuse into neighboring cancer cells, including those that may not strongly express HER2. This may help explain T-DXd’s activity even in heterogeneous tumors.

T-DXd already has FDA approvals for:

HER2-positive metastatic breast cancer (second-line and beyond)
HER2-low metastatic breast cancer (a broader category defined by lower HER2 expression)
HER2-ultralow metastatic breast cancer
HER2-positive metastatic gastric/gastroesophageal junction cancer
HER2-mutant metastatic non-small cell lung cancer

If the May 18 decision is favorable, the neoadjuvant HER2-positive early breast cancer indication would be added to this list. For context on how ADC technology works in a related breast cancer setting, see our detailed coverage of Dato-DXd and TROPION-Breast02 in triple-negative breast cancer.

The DESTINY-Breast11 Trial: Design and Results

Design

DESTINY-Breast11 (NCT05113251) was a global, multicenter, randomized, open-label Phase 3 trial conducted at 147 sites across 18 countries. It enrolled adults with previously untreated, high-risk HER2-positive early breast cancer, defined as tumors that were either T3 or larger with any nodal status, or any T stage with N1 to N3 nodal involvement (node-positive disease), including inflammatory breast cancer. The HER2-positive definition required either IHC 3+ or positive in situ hybridization. Patients were randomized in a 1:1:1 design across three arms:

T-DXd monotherapy arm: T-DXd 5.4 mg/kg every 3 weeks for 8 cycles (n=286), closed early
T-DXd-THP arm: T-DXd 5.4 mg/kg every 3 weeks for 4 cycles, then paclitaxel plus trastuzumab plus pertuzumab (THP) for 4 cycles (n=321)
ddAC-THP (control arm): Dose-dense doxorubicin plus cyclophosphamide every 2 weeks for 4 cycles, then THP for 4 cycles (n=320)

The T-DXd monotherapy arm was closed early in March 2024, following an Independent Data Monitoring Committee recommendation based on lower pCR rates than the combination arms and low likelihood of demonstrating superiority. This was a pre-specified adaptive design decision, not a safety signal.

Primary endpoint: pCR results

Outcome	T-DXd plus THP (n=321)	ddAC plus THP (n=320)
pCR rate (ypT0/is ypN0)	67.3%	56.3%
Absolute difference in pCR	+11.0 percentage points	—
p-value	0.003	—
Patients proceeding to surgery	97.2%	Comparable
EFS HR (immature, 4.5% events)	0.56 (95% CI 0.26 to 1.17)	Reference

Source: Harbeck N et al. Annals of Oncology. 2025. doi:10.1016/S0923-7534(25)04968-3. Presented at ESMO Congress 2025, Berlin. Abstract 291O.

The 11-point improvement in pCR rate is clinically meaningful by any standard in this disease. To put it in context: with existing standard-of-care regimens, pCR rates in high-risk HER2-positive disease range from approximately 39 to 64% depending on population characteristics and regimen. The DESTINY-Breast11 control arm (56.3%) sits in the middle of that range, reflecting an appropriately representative benchmark. The T-DXd-THP arm’s 67.3% is at the top of and above that historical range.

The benefit was consistent across pre-specified subgroups, including both hormone receptor-positive and hormone receptor-negative tumors, an important finding because HER2+/HR+ tumors historically have lower pCR rates and represent a more challenging treatment population.

What about long-term survival?

The EFS (event-free survival) hazard ratio of 0.56 suggests a 44% reduction in the rate of recurrence or death events in favor of T-DXd-THP numerically. However, EFS data maturity was only 4.5% at the time of the analysis, meaning very few events had occurred. The confidence interval (0.26 to 1.17) crosses 1.0, meaning the survival benefit is directionally promising but not yet statistically confirmed.

This is expected and appropriate for a neoadjuvant trial in early-stage cancer: these patients were diagnosed at a potentially curable stage, and survival events take years to accumulate. The FDA’s precedent for accepting pCR as a surrogate endpoint in the neoadjuvant setting means approval does not require mature survival data. More mature EFS and overall survival data from DESTINY-Breast11 will emerge over subsequent years and will be critical for confirming the long-term value of the pCR benefit.

Safety: Better Tolerability Than the Current Standard, With One Key Signal to Monitor

One of the most striking findings in DESTINY-Breast11 is not the efficacy. It is the safety comparison. The T-DXd-THP arm had substantially fewer severe adverse events than the anthracycline-based control.

Safety Metric	T-DXd plus THP	ddAC plus THP
Grade 3 or higher adverse events	37.5%	55.8%
Serious adverse events	10.6%	20.2%
Treatment interruptions	37.8%	54.5%
Left ventricular dysfunction (all grade)	1.3%	6.1%
ILD/pneumonitis (all grade)	4.4%	5.1%
Grade 3/4 ILD events	1	5
Grade 5 (fatal) ILD events	1	1
Treatment-related deaths (all causes)	1 (0.3%)	2 (0.6%)
Most common Grade 3 or higher AE	Neutropenia (13.8%)	Hematologic toxicity predominant
Fatigue (all grade)	41.3%	54.8%

The cardiac finding warrants specific emphasis. Doxorubicin (the “A” in AC chemotherapy) is associated with dose-dependent cardiotoxicity, including cardiomyopathy and heart failure, that can emerge during treatment and persist or worsen years later. The 6.1% rate of left ventricular dysfunction in the control arm versus 1.3% in the T-DXd-THP arm represents a clinically important difference in a population that will be living with the long-term consequences of treatment for decades.

The ILD signal: the key safety consideration for T-DXd Interstitial lung disease (ILD), inflammation and scarring of lung tissue, is the most important safety concern with T-DXd across all its indications. In DESTINY-Breast11, the all-grade ILD rate was 4.4% in the T-DXd-THP arm and 5.1% in the control arm, which are comparable. Most events were Grade 1 or 2 and manageable with dose modification and corticosteroids. However, there was one Grade 5 (fatal) ILD event in each arm, with the independent adjudication committee attributing one death in the T-DXd-THP arm to drug-related pneumonitis. This is not a reason to avoid the drug; one in each arm is a roughly comparable rate at this sample size. But ILD monitoring is a critical clinical requirement for T-DXd in practice. Current guidance requires baseline pulmonary assessment before starting T-DXd, prompt evaluation of any new or worsening respiratory symptoms (dyspnea, cough, fever), immediate T-DXd interruption if ILD is suspected, and corticosteroid treatment for confirmed cases. Providers switching to this regimen must be familiar with ILD surveillance protocols.

What This Means for Patients Navigating Treatment Right Now

If you have been diagnosed with HER2-positive breast cancer at stage II or III and are at the stage of discussing neoadjuvant treatment options with your oncologist, this FDA decision is directly relevant to your care.

If the FDA approves on May 18

T-DXd followed by THP would become an FDA-approved option for high-risk (stage II/III) HER2-positive early breast cancer, specifically for patients with node-positive disease (N1 to N3) or large tumors (T3 or larger).
Your oncologist may recommend this regimen over the current anthracycline-based standard, particularly if your tumor characteristics suggest high risk and you have cardiovascular risk factors that make doxorubicin’s cardiac effects a concern.
The treatment involves 4 cycles of T-DXd (intravenous, every 3 weeks), followed by 4 cycles of paclitaxel plus trastuzumab plus pertuzumab, then surgery. Post-surgery treatment depends on whether you achieved pCR.
If you have already started a neoadjuvant regimen: do not switch without discussion with your oncologist. Mid-treatment changes are complex and require careful individual assessment.

The treatment pathway after surgery

pCR does not mean treatment is finished. Patients who achieve pCR after neoadjuvant therapy typically continue with adjuvant trastuzumab with or without pertuzumab, and those with HR+ disease also receive endocrine therapy. Patients who do NOT achieve pCR currently receive adjuvant ado-trastuzumab emtansine (T-DM1/Kadcyla) to address the residual disease that proved resistant to neoadjuvant treatment.

A higher pCR rate means more patients entering that post-surgery phase in the most favorable prognostic position. For patients who still have residual disease, the adjuvant escalation pathway remains unchanged by this approval.

For related context on ADC mechanisms and how different ADCs work across breast cancer subtypes, see our post on vepdegestrant and the PROTAC mechanism in ESR1-mutated ER+ breast cancer and our analysis of Dato-DXd in triple-negative breast cancer.

Reading This Honestly: Context and Limitations

Survival data is immature

At 4.5% EFS maturity, we do not yet have confirmatory evidence that the pCR improvement translates into longer survival. The FDA’s precedent allows pCR as a surrogate, and the EFS directional signal (HR 0.56) is encouraging, but it is not yet proven. Patients and oncologists making decisions now are extrapolating from a strong surrogate, not from confirmed survival benefit. The maturing EFS and OS data from DESTINY-Breast11 will be the most important data to watch over the next several years.

Representation limitations

The published trial report specifically notes under-representation of Black or African American patients. This is a meaningful limitation in a disease where Black women are more likely to be diagnosed with aggressive subtypes and at advanced stages, and where outcomes disparities are well documented. Whether the pCR and safety results generalize fully to this population requires additional study and real-world evidence.

The monotherapy arm closed early

T-DXd monotherapy (without the THP sequence) achieved pCR rates of 43 to 51%, which is numerically inferior to both the combination arm and the control arm. The IDMC closed enrollment in that arm based on this finding. The approved regimen, if cleared, will be T-DXd followed by THP, not T-DXd alone. This distinction matters for clinical implementation.

What Happens on and After May 18

The PDUFA date is May 18, 2026. This is the deadline by which the FDA must complete its review. Decisions can come on or before this date.

If approved, T-DXd followed by THP would immediately be available to prescribers as the first ADC-based neoadjuvant regimen for HER2-positive early breast cancer. NCCN guideline updates and payer coverage decisions typically follow relatively quickly for priority FDA approvals, though individual insurance authorization timelines vary.

China has already approved this regimen based on the same DESTINY-Breast11 data. The European Medicines Agency review is ongoing. Regulatory validation across multiple agencies, if it follows, will strengthen the evidence base further.

We will update this post when the FDA’s ruling is announced.

Are you or a family member navigating a HER2-positive breast cancer diagnosis?

Treatment decisions in early breast cancer are among the most consequential and time-sensitive in oncology. If you have been recently diagnosed with HER2-positive stage II or III breast cancer, the most important step is consultation with a breast oncologist at a cancer center with expertise in HER2-directed therapies and access to current clinical trial data. The NCI-Designated Cancer Centers directory maintains a searchable list of specialized breast oncology programs. Susan G. Komen and the Metastatic Breast Cancer Alliance maintain patient navigation resources. We will continue tracking the FDA’s decision and the maturing DESTINY-Breast11 survival data as both become available.

Sources

Primary trial publication: Harbeck N et al. Neoadjuvant trastuzumab deruxtecan alone or followed by paclitaxel, trastuzumab, and pertuzumab for high-risk HER2-positive early breast cancer (DESTINY-Breast11): a randomised, open-label, multicentre, phase III trial. Annals of Oncology. 2025. doi:10.1016/S0923-7534(25)04968-3

PubMed: Harbeck N et al. DESTINY-Breast11. PubMed. PMID: 41130363.

ESMO 2025 abstract: Harbeck N et al. DESTINY-Breast11: Neoadjuvant T-DXd alone or followed by THP vs SOC for high-risk HER2+ eBC. ESMO Congress 2025. Abstract 291O.

DESTINY-Breast11 trial registration: NCT05113251. ClinicalTrials.gov.

AstraZeneca/Daiichi Sankyo press release: Enhertu followed by THP before surgery resulted in a pathologic complete response in 67% of patients in DESTINY-Breast11 Phase III trial. astrazeneca.com. October 18, 2025.

Targeted Oncology trial coverage: DESTINY-Breast11: Neoadjuvant T-DXd/THP Improves pCR in High-Risk HER2+ BC. targetedonc.com. October 2025.

FDA surrogate endpoint resource: Surrogate Endpoint Resources for Drug and Biologic Development. FDA.gov.

T-DM1 FDA approval: FDA approves ado-trastuzumab emtansine for HER2-positive breast cancer. FDA.gov.

Patient resources: NCI Cancer Center directory | Susan G. Komen | MBC Alliance | NCCN Breast Cancer Guidelines

Disclaimer: Health Evidence Digest provides general information about clinical trials and FDA regulatory processes for educational purposes. This content is not a substitute for professional medical advice, diagnosis, or treatment. Decisions about breast cancer treatment, including neoadjuvant therapy, should be made in close consultation with a qualified oncologist who can account for your individual diagnosis, tumor characteristics, and health status.

May 19, 2026

The First BCL-2 Inhibitor Specifically Approved for Mantle Cell Lymphoma Just Received FDA Clearance. Here Is What the Data Shows.

📌 The essentials Drug: Beqalzi (sonrotoclax) — a next-generation, highly selective BCL-2 inhibitor. FDA approval type: Accelerated approval on May 13, 2026. Continued approval may depend on confirmatory clinical trial results. Developer: BeOne Medicines USA, Inc. (formerly BeiGene). Indication: Adults with relapsed or refractory mantle cell lymphoma (MCL) after at least two prior lines of systemic therapy, including a Bruton’s tyrosine kinase (BTK) inhibitor. What makes it first-in-class: First and only BCL-2 inhibitor specifically approved for MCL. Venetoclax (Venclexta) is approved for CLL and AML but not MCL. Key trial results (BGB-11417-201, n=103): ORR 52% (95% CI 42–62%), median duration of response 15.8 months, median time to response 1.9 months. Dosing: Oral tablet, once daily with food, following a 4-week dose ramp-up schedule. Target dose: 320 mg once daily. Critical warning: Tumor lysis syndrome (TLS) — potentially life-threatening. Requires risk assessment, prophylaxis, and close monitoring throughout the ramp-up phase. Regulatory designations: Breakthrough Therapy, Fast Track, Orphan Drug, Priority Review. Reviewed under Project Orbis.

Mantle cell lymphoma does not follow the forgiving course of many lymphoma subtypes. It is aggressive. It responds to first-line therapy in many patients, but it almost always comes back. After a first relapse on BTK inhibitor therapy, which has been the most important treatment advance in MCL over the past decade, options narrow considerably. Response rates with available agents are often modest. Duration of response can be brief. A population of patients with limited alternatives and deteriorating disease has been waiting for something new to try.

On May 13, 2026, the FDA granted accelerated approval to Beqalzi (sonrotoclax) for adults with relapsed or refractory MCL after at least two prior lines of therapy including a BTK inhibitor. Beqalzi is a BCL-2 inhibitor, and it is the first drug in that class specifically approved for mantle cell lymphoma. The pivotal trial in 103 patients showed a 52% overall response rate and a median duration of response of 15.8 months, with a notably high response rate in TP53-mutant patients who typically fare poorly with existing options.

Mantle Cell Lymphoma: Why Post-BTK Relapse Is Such a Difficult Problem

Mantle cell lymphoma (MCL) is a rare, aggressive B-cell non-Hodgkin lymphoma that originates in the mantle zone of the lymph node. It accounts for approximately 5% of non-Hodgkin lymphoma cases globally, with roughly 3,300 new diagnoses annually in the United States. The median age at diagnosis is approximately 65, and the disease is more common in men.

MCL is characterized biologically by the t(11;14) chromosomal translocation, which places the CCND1 gene encoding cyclin D1 under the control of an immunoglobulin heavy chain promoter, driving overexpression of cyclin D1 and uncontrolled cell proliferation. Most MCL tumors also dysregulate the BCL-2 anti-apoptotic pathway, which helps cancer cells survive even when they should die. These two biological features, the proliferative driver and the survival mechanism, are both targets for therapy.

BTK inhibitors (ibrutinib, acalabrutinib, zanubrutinib) transformed the treatment of MCL at first and second relapse, producing high response rates in the 70-80% range. But responses are not permanent. Most patients eventually progress on BTK inhibitor therapy. At that point, the disease has developed resistance mechanisms, the patient has typically accumulated treatment-related organ stress, and available next-line options have produced response rates in the 20-40% range with short durations.

TP53 mutations: the highest-risk subgroup in MCL TP53 encodes p53, the tumor suppressor protein that normally triggers cell death when DNA damage occurs. TP53 mutations are present in approximately 20–30% of MCL patients and are strongly associated with chemotherapy resistance, shorter remission durations, and worse overall survival. Patients with TP53-mutant MCL represent one of the highest-unmet-need populations in hematologic oncology. Standard chemotherapy regimens, which work partly through DNA damage that requires functional p53 to trigger apoptosis, are less effective when p53 is mutated. In the BGB-11417-201 trial supporting Beqalzi’s approval, the TP53-mutant subgroup achieved an ORR of 59.1%, numerically higher than the 52% overall population response rate. This is the opposite of what is typically seen with chemotherapy-based regimens in this subgroup, and it supports the mechanistic hypothesis that BCL-2 inhibition can bypass p53-dependent pathways to induce cancer cell death.

How BCL-2 Inhibition Works and What Makes Sonrotoclax Different from Venetoclax

BCL-2 (B-cell lymphoma 2) is a protein that promotes cell survival by blocking apoptosis, the programmed cell death process that the body uses to eliminate damaged, aged, or abnormal cells. In normal cells, BCL-2 is part of a balanced system of pro- and anti-apoptotic proteins. In many B-cell malignancies, BCL-2 is overexpressed, tipping the balance toward survival and allowing cancer cells to accumulate rather than die.

BCL-2 inhibitors work by occupying the BH3-binding groove of the BCL-2 protein and displacing the pro-apoptotic proteins it normally sequesters. When these pro-apoptotic proteins are released, they activate the mitochondrial apoptosis cascade, triggering cell death. This mechanism is independent of TP53 function, which explains why BCL-2 inhibitors can be active in TP53-mutant tumors that resist DNA-damaging chemotherapy.

Sonrotoclax versus venetoclax

Venetoclax (Venclexta) is the established BCL-2 inhibitor in the market, approved for chronic lymphocytic leukemia (CLL) and acute myeloid leukemia (AML). It has been used off-label in MCL with modest activity. Sonrotoclax was engineered with greater potency and selectivity for BCL-2 compared to venetoclax, targeting BCL-2 more precisely while having less activity against the related BCL-XL protein.

Feature	Sonrotoclax (Beqalzi)	Venetoclax (Venclexta)
BCL-2 selectivity	Higher selectivity for BCL-2; reduced BCL-XL activity	BCL-2 selective; BCL-XL activity also noted
FDA-approved for MCL	Yes — May 13, 2026 (accelerated)	No — approved for CLL and AML only
Approved indications	R/R MCL after ≥2 lines including BTK inhibitor	CLL (with obinutuzumab or ibrutinib), R/R AML (with azacitidine or decitabine)
Target dose	320 mg once daily (after 4-week ramp-up)	400 mg once daily (after 5-week ramp-up for CLL)
Tumor lysis syndrome risk	Yes — requires ramp-up and prophylaxis	Yes — requires ramp-up and prophylaxis
Route	Oral, once daily with food	Oral, once daily with food

The BGB-11417-201 Trial: Design and Results

Trial design

BGB-11417-201 (NCT05471843) is a single-arm, multicenter, open-label Phase 1/2 trial. Part 1 established the safety, tolerability, and recommended Phase 2 dose (RP2D) of sonrotoclax through dose escalation. No dose-limiting toxicities were observed during this phase, and 320 mg once daily was identified as the RP2D. Part 2 evaluated sonrotoclax at the 320 mg RP2D following a 4-week dose ramp-up schedule in patients with relapsed or refractory MCL.

Eligibility for the efficacy-evaluable population required: histologically confirmed MCL, at least one prior anti-CD20-based therapy, at least one prior BTK inhibitor, ECOG performance status 0-2, adequate organ function, and no prior BCL-2 inhibitor therapy.

Efficacy results

Endpoint	Result
Study population (Part 2)	103 adults with R/R MCL; median age 68; all received prior anti-CD20 and BTK inhibitor
Prior lines of therapy (median)	3 (range 2–9)
Overall response rate (ORR)	52% (95% CI 42–62%; 1-sided p<0.0001)
Complete response (CR) rate	15.5% (95% CI 9.1–24.0%)
Partial response (PR) rate	36.9%
Median time to first response	1.9 months (range 1.6–6.2 months)
Median duration of response (DOR)	15.8 months (95% CI 7.4 months to not estimable)
Median follow-up (efficacy analysis)	11.9 months (per IRC) / 14.2 months (per Targeted Oncology)
TP53-mutant subgroup ORR	59.1%
Assessment method	Independent review committee (IRC) using Lugano criteria

Source: FDA press release May 13, 2026. AJMC, ASCO Post, CancerNetwork, Targeted Oncology. BGB-11417-201, NCT05471843.

A 52% ORR in a heavily pre-treated population, many of whom had BTK inhibitor-resistant disease after a median of three prior lines of therapy, is a meaningful result. The 15.8-month median DOR is also notable in a disease where post-BTK responses often last only a few months. The upper bound of the DOR confidence interval (not estimable) at a median follow-up of approximately 12 months suggests that a proportion of responses were still ongoing at the time of analysis.

The TP53-mutant subgroup ORR of 59.1% is the most clinically significant finding for oncologists. Standard chemotherapy regimens are typically less effective in TP53-mutant MCL, and a response rate numerically higher in this subgroup than in the overall population suggests that BCL-2 inhibition may offer the most value precisely where current options are least effective.

What accelerated approval means for this drug The FDA’s accelerated approval pathway allows earlier approval of drugs for serious conditions based on a surrogate endpoint (in this case, ORR and DOR) that is reasonably likely to predict clinical benefit, while requiring the sponsor to conduct confirmatory trials demonstrating actual clinical benefit such as overall survival. For Beqalzi, continued approval may depend on the results of confirmatory studies. BeOne Medicines is conducting a broader clinical program for sonrotoclax, including combination studies with BTK inhibitors (notably zanubrutinib, also a BeOne Medicine product) in MCL and other B-cell malignancies. If those studies demonstrate clinical benefit, the accelerated approval pathway to full approval becomes available. For patients with relapsed or refractory MCL who have exhausted prior lines of therapy, accelerated approval provides access to an investigational drug that has demonstrated meaningful activity now, rather than waiting for the confirmatory trial to complete. This is the intended purpose of the pathway for serious, life-threatening conditions.

Safety: The TLS Warning That Requires Proactive Management

Tumor lysis syndrome: the primary safety concern

Tumor lysis syndrome is the most serious safety concern for Beqalzi, shared with venetoclax and other potent agents that rapidly kill large numbers of cancer cells. When cancer cells die quickly, they release their contents into the bloodstream: potassium, phosphate, nucleic acids, and uric acid. The kidneys may not be able to clear this influx quickly enough, leading to a metabolic emergency that can cause kidney failure, life-threatening cardiac arrhythmias, seizures, and death.

Beqalzi’s prescribing information requires the following TLS management steps:

Pre-treatment risk assessment: Evaluate the patient’s baseline risk of TLS based on tumor bulk, renal function, and uric acid levels before starting Beqalzi.
Prophylactic hydration: Patients should drink 6 to 8 glasses (approximately 1.5 to 2 liters) of water daily starting 1 to 2 days before the first dose, on the day of the first dose, on any day the dose is increased, and when restarting treatment.
Anti-hyperuricemic agents: Healthcare providers may prescribe allopurinol or rasburicase before and during the dose ramp-up to reduce uric acid levels.
Blood monitoring: Blood tests for TLS markers (potassium, phosphate, uric acid, creatinine) are required before and during treatment, especially during the 4-week ramp-up.
4-week ramp-up schedule: Doses are increased stepwise over 4 weeks to reach the 320 mg target dose, reducing the rate of cell death at any one time and lowering TLS risk. Strong CYP3A inhibitors are contraindicated during the ramp-up phase as they increase sonrotoclax exposure.

Other important safety findings from the trial

Serious adverse reactions occurred in 37% of patients in the trial, with pneumonia the most common serious adverse reaction at 10%. Grade 3 or 4 laboratory abnormalities occurring in at least 15% of patients included decreased lymphocyte counts and decreased neutrophil counts. The most common adverse reactions overall were pneumonia, fatigue, edema, diarrhea, and upper respiratory tract infection.

The prescribing information also carries warnings for serious infections (including fatal infections) and neutropenia, both of which require monitoring. Patients on Beqalzi who develop fever, chills, or other signs of infection should contact their oncology team promptly.

Beqalzi carries an embryo-fetal toxicity warning. Women of childbearing potential and male patients with female partners who could become pregnant must use effective contraception during treatment and for one week after the last dose.

Dosing and Administration: The 4-Week Ramp-Up Schedule

Ramp-up week	Daily dose	Key requirement
Week 1 (days 1–7)	20 mg once daily	TLS monitoring; avoid strong CYP3A inhibitors
Week 2 (days 8–14)	80 mg once daily	TLS monitoring; hydration continued
Week 3 (days 15–21)	160 mg once daily	Blood tests for TLS markers
Week 4 (days 22–28)	240 mg once daily	Continue monitoring
Week 5 onward	320 mg once daily	Target dose reached; once-daily dosing with food continues

Beqalzi tablets are available in four strengths (1 mg, 5 mg, 20 mg, and 80 mg) to allow precise dosing throughout the ramp-up schedule. All doses should be taken with food. If a dose is missed and it is more than 8 hours since the scheduled time, skip that dose and take the next scheduled dose at the regular time.

The CYP3A inhibitor contraindication during ramp-up: a clinically important interaction Sonrotoclax is metabolized by CYP3A4. Strong CYP3A inhibitors, including azole antifungals (fluconazole, voriconazole, itraconazole), certain macrolide antibiotics (clarithromycin), and HIV protease inhibitors, significantly increase sonrotoclax exposure. This dramatically increases TLS risk during the ramp-up phase when doses are already being escalated. Starting Beqalzi or increasing the dose while a patient is taking a strong CYP3A inhibitor is contraindicated. Moderate CYP3A inhibitors require dose reduction. Patients and prescribers should review all concomitant medications carefully before initiating and during the ramp-up phase. If a patient needs to restart Beqalzi after a treatment break, the full ramp-up schedule must be repeated. This is an important point for patients who interrupt treatment due to adverse events or procedures.

🔗 Also on HED: The FDA’s Real-Time Clinical Trials Initiative: AstraZeneca’s TRAVERSE Trial Involves the Same Drug Class Our post on the FDA’s April 2026 real-time clinical trials pilot covers the TRAVERSE trial, which studies acalabrutinib + venetoclax + rituximab in treatment-naive MCL at MD Anderson and UPenn. The combination of BTK inhibition and BCL-2 inhibition in the same patient population where Beqalzi is now approved for later lines illustrates how the MCL treatment landscape is being built out.

What This Means for Patients with Relapsed Mantle Cell Lymphoma

Beqalzi is specifically for patients who have already received at least two prior lines of therapy including a BTK inhibitor. It is not a first-line or second-line therapy. For patients currently in earlier stages of MCL treatment, this approval does not change the immediate treatment path.

For patients who have received both a chemoimmunotherapy regimen and a BTK inhibitor and whose disease has progressed, Beqalzi now provides an FDA-approved BCL-2 inhibitor option with a 52% response rate and a median response duration of 15.8 months in a clinical trial population that closely reflects this setting.

Questions to discuss with your hematologist or oncologist if you or a family member is in this situation:

Am I eligible for Beqalzi based on my treatment history? The requirement is at least two prior lines including a BTK inhibitor, with no prior BCL-2 inhibitor.
What is my TLS risk profile, and what monitoring and prophylaxis will I need before and during the ramp-up?
Are there clinical trials of sonrotoclax in combination with other agents that might be appropriate for my specific situation?
Are there confirmatory trials I could participate in that would contribute to the evidence base for this drug?

Resources for patients with mantle cell lymphoma

For patients navigating MCL treatment decisions, the Lymphoma Research Foundation maintains patient education resources on MCL specifically, including information on clinical trial participation. The NCI’s Cancer Center directory can help identify centers with dedicated lymphoma programs and access to the newest approved therapies. For Beqalzi specifically, BeOne Medicines’ patient support program information will be available through the treating oncologist or hematologist at prescribing.

Sources

FDA accelerated approval announcement: FDA grants accelerated approval to sonrotoclax (Beqalzi) for relapsed or refractory mantle cell lymphoma. FDA.gov. May 13, 2026.

AJMC coverage: Sonrotoclax Granted Accelerated Approval for R/R Mantle Cell Lymphoma. ajmc.com. May 13, 2026.

Hematology Advisor: FDA Grants Accelerated Approval to Beqalzi for R/R Mantle Cell Lymphoma. hematologyadvisor.com. May 2026.

OncLive: FDA Approves Sonrotoclax for Relapsed/Refractory Mantle Cell Lymphoma. onclive.com. May 13, 2026.

CancerNetwork: FDA Approves Sonrotoclax in Relapsed/Refractory Mantle Cell Lymphoma. cancernetwork.com. May 2026.

Targeted Oncology: FDA Approves Next-Gen BCL2 Inhibitor Sonrotoclax for R/R Mantle Cell Lymphoma. targetedonc.com. May 2026.

CURE Today: FDA Approves Beqalzi for Relapsed Mantle Cell Lymphoma. curetoday.com. May 2026.

ASCO Post: Sonrotoclax Receives Accelerated Approval in Relapsed or Refractory MCL. ascopost.com. May 2026.

Oncology Nursing News: FDA Approves Sonrotoclax for R/R Mantle Cell Lymphoma. oncnursingnews.com. May 2026.

Drugs.com drug information: Beqalzi (sonrotoclax): Uses, Dosage, Side Effects, Warnings. drugs.com.

Trial registration: BGB-11417-201. A Study of Sonrotoclax (BGB-11417) in Participants With B-Cell Malignancies. NCT05471843. clinicaltrials.gov.

Patient resources: Lymphoma Research Foundation: lymphoma.org; NCI Cancer Centers: cancer.gov/research/nci-role/cancer-centers

Disclaimer: Health Evidence Digest provides general information about FDA approvals and health research for educational purposes. This content is not a substitute for professional medical advice. Beqalzi is approved under the accelerated approval pathway, and continued approval may depend on confirmatory trial results. All treatment decisions for mantle cell lymphoma should be made in close consultation with a qualified hematologist or oncologist.

May 18, 2026

Another Interchangeable Basal Insulin Just Received FDA Approval. Here Is What Langlara Is, Who It Is For, and What the Access Conversation Still Needs.

The essentials: On April 29, 2026, the FDA approved Langlara (insulin glargine-aldy), a biosimilar to Lantus (insulin glargine, Sanofi) developed by Lannett Company and its subsidiary Lanexa Biologics in partnership with Sunshine Lake Pharma. It is the third interchangeable insulin glargine biosimilar approved in the United States, after Semglee (2021) and Rezvoglar (2022). Interchangeable designation: pharmacists may substitute Langlara for a Lantus prescription without calling the prescriber first, subject to state pharmacy laws. Approved populations: adults and pediatric patients with type 1 diabetes, and adults with type 2 diabetes. Clinical basis: a comprehensive analytical, preclinical, and clinical program including Phase 1 PK/PD study NCT05248841 comparing insulin glargine-aldy to insulin glargine in healthy adults. Important caveat: pricing and launch date have not been publicly announced. Whether Langlara improves real-world access for patients who currently ration insulin depends almost entirely on pricing and formulary decisions not yet made.

Approximately 8.4 million Americans require insulin to survive or to manage their diabetes. For many of them, affording that insulin is not straightforward. Lantus, the most prescribed basal insulin in the world, carries a list price of several hundred dollars per month without insurance. Published surveys estimate that 1 in 4 people with diabetes in the United States reports rationing or skipping doses because of cost.

On April 29, 2026, the FDA approved Langlara (insulin glargine-aldy), a biosimilar to Lantus developed by Lannett Company and its subsidiary Lanexa Biologics in partnership with Sunshine Lake Pharma. The approval carries an interchangeable designation, meaning pharmacists may substitute it for Lantus at the counter without contacting the prescriber first, in states that permit such substitution.

Langlara is the third interchangeable insulin glargine biosimilar approved in the United States, after Semglee (insulin glargine-yfgn) in 2021 and Rezvoglar (insulin glargine-aglr) in 2022. Whether a third entry meaningfully improves access for patients depends almost entirely on pricing and formulary decisions that have not yet been publicly announced.

What Insulin Glargine Is and Why Basal Insulin Matters

Insulin glargine is a long-acting insulin analog engineered to provide steady, predictable background insulin coverage over approximately 24 hours. The body requires two types of insulin coverage: basal, which suppresses the liver’s continuous glucose output between meals and overnight, and bolus, which handles the glucose spike that follows eating. People with type 1 diabetes produce no insulin at all and require both. Many people with type 2 diabetes eventually require basal insulin when oral medications and lifestyle changes no longer provide adequate glycemic control.

Insulin glargine (Lantus) was the first long-acting analog approved to replace older NPH insulin, which had a pronounced peak effect and required twice-daily dosing in many patients. Lantus’s flat, peakless 24-hour profile allowed once-daily dosing with lower rates of nocturnal hypoglycemia. Since its original approval in 2000, it became the most widely prescribed basal insulin in the world.

Why insulin was reclassified as a biologic, and why that matters for biosimilars Until 2020, insulin in the United States was regulated as a drug under the Federal Food, Drug, and Cosmetic Act rather than as a biologic. This meant insulin could not be approved via the biosimilar pathway under the Biologics Price Competition and Innovation Act (BPCIA), the legal framework that allows biosimilars to enter the market and compete with reference products. In March 2020, all insulin products were transitioned to biologic status under the BPCIA. This opened the regulatory pathway for true interchangeable biosimilar approvals for insulin products, with the potential for pharmacy-level substitution. Semglee became the first interchangeable insulin biosimilar in July 2021, followed by Rezvoglar, and now Langlara. The transition also means that the FDA interchangeability standard, which requires switching studies demonstrating no loss of efficacy or increase in adverse events when alternating between the biosimilar and the reference product, now applies to insulin biosimilars.

Biosimilar Versus Interchangeable: A Distinction That Matters at the Pharmacy Counter

Not all biosimilars are interchangeable, and the distinction has real consequences for how patients access the product.

	Biosimilar only	Interchangeable biosimilar
FDA standard	Highly similar to reference product; no clinically meaningful differences in safety, purity, or potency	All biosimilar standards plus: switching studies showing no greater risk than reference product when alternating
Pharmacy substitution	Cannot be substituted automatically; requires new prescription or prescriber authorization in most states	Pharmacist may substitute for the reference product without calling the prescriber, subject to state law
Patient impact	Access depends on prescriber writing specifically for the biosimilar or insurer mandating it	Patient may receive the biosimilar on a Lantus prescription without any additional action from their doctor
Langlara status	Yes	Yes, interchangeable designation granted April 29, 2026

The interchangeable designation requires manufacturers to conduct switching studies in which patients alternate between the biosimilar and the reference product at least three times, to confirm there is no loss of efficacy or increase in adverse events from switching. For Langlara, the approval was based on a comprehensive analytical, preclinical, and clinical program including Phase 1 PK/PD study NCT05248841, comparing insulin glargine-aldy to insulin glargine in healthy adults, along with the broader analytical and preclinical data package.

The Insulin Glargine Landscape: Three Interchangeable Biosimilars, One Reference Product

Product	Maker	FDA approved	Status
Lantus (insulin glargine)	Sanofi	2000	Reference product
Basaglar (insulin glargine-aglr)	Eli Lilly	2015	Biosimilar only (not interchangeable); launched 2016
Semglee (insulin glargine-yfgn)	Biocon/Viatris	2021	First interchangeable insulin biosimilar; launched at approximately $148 per 5-pack vs. Lantus approximately $340 to $520 per month
Rezvoglar (insulin glargine-aglr)	Eli Lilly	2022	Second interchangeable biosimilar; launched April 2023 at $92 per 5-pack (77% below Lantus list price)
Langlara (insulin glargine-aldy)	Lannett/Lanexa/Sunshine Lake	April 29, 2026	Third interchangeable biosimilar; pricing and launch date not yet announced

The competitive pricing history of this space is instructive. When Semglee launched as the first interchangeable biosimilar in 2021, it priced at a wholesale acquisition cost of approximately $148 per package of five prefilled pens, compared with $340 to $520 per month for Lantus without insurance. Eli Lilly’s Rezvoglar entered in April 2023 at $92 per 5-pack, setting a new low-price benchmark. Whether Langlara will compete at or below these levels has not been disclosed.

For context on how the biosimilar market is evolving in another drug class, see our post on PONLIMSI and the crowded denosumab biosimilar landscape, where 19 FDA approvals have produced only modest savings for patients due to the same rebate dynamics described below.

For related coverage of what is changing in the broader insulin landscape, see our post on Awiqli, the first once-weekly basal insulin approved for type 2 diabetes in 2026.

The Access Question: Why Regulatory Approval Is Not the Same as Affordable Access

An FDA approval of an interchangeable biosimilar is a necessary condition for improved insulin access. It is not, on its own, sufficient. The history of insulin biosimilars in the United States illustrates the gap.

Semglee launched in 2021 with a list price meaningfully below Lantus. But list prices are not what most insured patients pay: pharmacy benefit managers (PBMs) negotiate rebates with manufacturers, and those rebate arrangements often favor the originator product on formulary even when a biosimilar carries a lower list price. The result is that biosimilar insulin market penetration in the United States has grown more slowly than in Europe, where national procurement systems and institutional substitution policies have driven biosimilar adoption rates above 90% in some countries.

California’s CalRx Biosimilar Insulin Initiative offers a different model. As of January 1, 2026, CalRx-branded insulin glargine pens became available to California residents at $55 for a five-pack through a state partnership with Civica Rx and Biocon Biologics, regardless of insurance status. That price point, enabled by state procurement rather than commercial market dynamics, illustrates what becomes possible when the insulin access question is addressed as a public health problem rather than a market competition question.

For Langlara specifically, Lanexa Biologics has stated its intention to pursue broad formulary placement across all commercial channels. Whether that translates to meaningful out-of-pocket savings for the 1 in 4 diabetes patients who report difficulty affording insulin will depend on the specific list price set at launch and the formulary tier negotiations that follow.

What patients transitioning to any insulin glargine biosimilar should know No dose conversion is required when switching between interchangeable insulin glargine products. The biosimilar delivers the same clinical effect at the same dose as Lantus. Blood glucose monitoring is still recommended during any transition period, as individual insulin requirements can vary based on factors unrelated to the product switch itself. Device differences matter. Langlara is supplied as a prefilled pen. Lantus is available in both a prefilled pen and a vial. If your current regimen uses a vial and your pharmacy substitutes a prefilled pen, confirm the administration steps with your pharmacist or diabetes care team. If your pharmacist has substituted a biosimilar for Lantus, they are required by law to notify you and your prescriber of the substitution in states with such requirements. Ask your pharmacist about the specific rules in your state. If you have concerns about a substitution, you or your prescriber can request that a specific product be dispensed by noting “dispense as written” on the prescription.

Safety Profile: Consistent With the Insulin Glargine Class

As an interchangeable biosimilar, Langlara is expected to have the same clinical profile as Lantus. Warnings, precautions, and adverse reactions apply to the insulin glargine class as a whole.

Hypoglycemia: The most clinically important risk of any insulin therapy. Severe hypoglycemia can be life-threatening. Risk increases with missed meals, excessive exercise, alcohol use, renal impairment, and co-administration with other glucose-lowering agents including sulfonylureas.
Medication errors: Insulin concentration errors are a documented source of patient harm. Langlara is U-100 (100 units per mL). Never use U-100 insulin in a syringe designed for a different concentration. Do not mix insulin glargine with other insulins.
Hypokalemia: Insulin drives potassium into cells. Monitoring of potassium is important in patients at risk, including those with renal disease or on medications that lower potassium.
Hypersensitivity: Severe or life-threatening hypersensitivity reactions, including anaphylaxis, have been reported with insulin products. Discontinue and seek emergency care if systemic hypersensitivity occurs.
Thiazolidinediones (TZDs): Pioglitazone and similar drugs used alongside insulin can cause fluid retention and increase the risk of heart failure. Patients on both should be monitored for signs of fluid retention.
Injection site reactions: Lipodystrophy (skin thickening or pitting at injection sites) can develop with repeated injections at the same site. Rotate injection sites within the recommended areas (abdomen, thigh, deltoid).

What This Approval Means in Practice

Langlara’s approval adds a third interchangeable insulin glargine biosimilar to the U.S. market. The interchangeable designation is meaningful: it allows pharmacy-level substitution without a new prescription, which reduces one logistical barrier to biosimilar uptake. Whether it reduces the financial barrier depends on what Lanexa Biologics announces for pricing and formulary positioning at launch.

For patients currently on Lantus or another insulin glargine product, the most useful resources while commercial pricing evolves are the American Diabetes Association, which maintains current guidance on insulin assistance programs and state programs, and InsulinHelp.org, a nonprofit directory of insulin access resources. The JDRF also maintains updated insulin affordability resources specifically for people with type 1 diabetes.

For more on how biosimilar approvals interact with real-world access, and why regulatory clearance does not automatically translate to patient savings in the U.S. market, see our post on PONLIMSI and the denosumab biosimilar landscape.

Sources

Lannett/Lanexa/Sunshine Lake press release: Lannett Company, Lanexa Biologics and Sunshine Lake Pharma announce FDA Approval of LANGLARA (insulin glargine-aldy). BioSpace. May 4, 2026.

Drugs.com approval history: Langlara (insulin glargine-aldy) FDA Approval History. drugs.com.

Drug Topics: FDA Approves Langlara as Interchangeable Biosimilar to Insulin Glargine. drugtopics.com. May 2026.

Pharmacy Times: FDA Approves New Interchangeable Biosimilar of Insulin Glargine. pharmacytimes.com. May 2026.

Endocrinology Advisor: Langlara Receives FDA Nod as Interchangeable Lantus Alternative. endocrinologyadvisor.com. May 2026.

Contemporary Pediatrics: FDA approves interchangeable insulin glargine-aldy for type 1 and type 2 diabetes. contemporarypediatrics.com. May 2026.

FDA prescribing information: LANGLARA (insulin glargine-aldy) Prescribing Information. BLA 761412. FDA.gov. 2026.

Phase 1 PK/PD study registration: NCT05248841. A Study to Assess the Pharmacokinetics and Pharmacodynamics of Insulin Glargine-ALDY Versus Insulin Glargine. ClinicalTrials.gov.

Semglee FDA approval: FDA approves Semglee, first interchangeable biosimilar insulin. FDA.gov. 2021.

Rezvoglar FDA approval: FDA approves insulin glargine-aglr (Rezvoglar). FDA.gov. 2022.

CalRx Biosimilar Insulin Initiative: CalRx. $55 per 5-pack prefilled pen. calrx.ca.gov. January 2026.

FDA interchangeable biosimilars: Biosimilar and Interchangeable Products. FDA.gov.

FDA BPCIA framework: Biosimilar Development, Review, and Approval. FDA.gov.

PBM market structure: Pharmacy Benefit Managers. PMC7748166.

Patient resources: American Diabetes Association | InsulinHelp.org | JDRF insulin affordability resources | CalRx insulin program

Disclaimer: Health Evidence Digest provides general information about FDA approvals and health research for educational purposes. This content is not a substitute for professional medical advice. All insulin therapy decisions, including switching between products, should be made in consultation with your diabetes care provider or endocrinologist.

May 17, 2026

Two Pills Instead of Three, No Tenofovir, No INSTI. The FDA Just Approved a New Way to Maintain HIV Suppression.

The essentials: On April 20, 2026, the FDA approved Idvynso (doravirine/islatravir, Merck) as a once-daily, two-drug complete HIV-1 treatment regimen for adults who are already virologically suppressed. Available in pharmacies from May 11, 2026. Who qualifies: adults with HIV-1 RNA less than 50 copies/mL on a stable regimen, with no history of virologic treatment failure and no known resistance to doravirine. What makes it clinically distinctive: it is the first non-INSTI, tenofovir-free, complete two-drug regimen to demonstrate non-inferior efficacy versus Biktarvy (bictegravir/emtricitabine/tenofovir alafenamide), the most widely prescribed HIV regimen in the world, in a double-blind head-to-head Phase 3 trial. It also introduces islatravir, the first approved drug in a new antiretroviral class called NRTTIs, into clinical practice. What it is not: a treatment-initiation option for people starting HIV therapy for the first time. It is a switch regimen only. Key contraindications: must not be co-administered with lamivudine (3TC) or emtricitabine (FTC), or strong CYP3A4 inducers including rifampin, carbamazepine, phenytoin, and St. John’s Wort.

For anyone living with HIV who is currently well-controlled on antiretroviral therapy, the treatment goal is not just viral suppression. It is viral suppression with the least cumulative burden on the body, the fewest side effects, and the simplest possible regimen. Decades of HIV drug development have been moving steadily in that direction: from multiple daily doses of multiple drugs in the 1990s, to once-daily combinations, to single-tablet regimens, to now, two-drug regimens that can maintain suppression without some of the drug classes that current three-drug standards rely on.

On April 20, 2026, the FDA approved Idvynso (doravirine/islatravir, pronounced ihd-VIHN-so), a once-daily tablet from Merck combining two drugs with distinct mechanisms. It is indicated as a complete treatment regimen to replace current antiretroviral therapy in adults with HIV-1 who are already virologically suppressed. Available in pharmacies from May 11, 2026.

Idvynso is the first non-INSTI, tenofovir-free, once-daily, two-drug complete regimen to demonstrate non-inferior efficacy versus the current three-drug gold standard, Biktarvy (bictegravir/emtricitabine/tenofovir alafenamide), in a head-to-head Phase 3 trial. It also introduces islatravir, the first drug in a new antiretroviral class, into approved clinical practice.

Why the Non-INSTI, Tenofovir-Free Distinction Matters

Most people living with HIV in the United States are on a regimen that includes either an integrase strand transfer inhibitor (INSTI), tenofovir, or both. INSTIs (bictegravir, dolutegravir, cabotegravir) are highly effective and well tolerated by most patients, but they carry a well-documented association with weight gain and metabolic effects in some people. Tenofovir, particularly the older tenofovir disoproxil fumarate (TDF), carries renal and bone density concerns with long-term use, though the newer tenofovir alafenamide (TAF) formulation substantially reduced those risks.

Idvynso contains neither. Doravirine is a non-nucleoside reverse transcriptase inhibitor (NNRTI) with a clean metabolic profile, established since its approval in 2018 as Pifeltro. Islatravir is an NRTTI, a distinct class that works differently from both NRTIs and INSTIs. For patients who experience weight gain, lipid changes, or bone effects on current regimens, or who have renal concerns that make tenofovir management complex, a non-INSTI, tenofovir-free option backed by head-to-head Phase 3 data represents a meaningful new clinical choice.

Who qualifies to switch to Idvynso Idvynso is a switch regimen, not a treatment-initiation option. It is approved for adults with HIV-1 who meet all of the following criteria: Currently virologically suppressed, meaning HIV-1 RNA less than 50 copies/mL on a stable antiretroviral regimen; no history of virologic treatment failure; no known resistance substitutions associated with resistance to doravirine. Idvynso is not approved for treatment-naive patients (those starting HIV treatment for the first time) or for patients with prior virologic failure on any regimen. The doravirine resistance requirement specifically means patients with documented NNRTI resistance mutations affecting doravirine are not candidates.

How Idvynso Works: Two Drugs, Two Distinct Mechanisms

Doravirine: the established NNRTI

Doravirine (100 mg) is an NNRTI that noncompetitively binds to and inhibits HIV-1 reverse transcriptase. It has been FDA-approved since 2018, first as Pifeltro (standalone single agent) and then in the three-drug combination Delstrigo (doravirine/lamivudine/tenofovir disoproxil fumarate). Its established safety profile in approved use includes a notably clean metabolic record: minimal effects on fasting lipids, insulin resistance, and body weight in clinical trials, in contrast to some other antiretrovirals.

Islatravir: the first-in-class NRTTI

Islatravir (0.25 mg) is a nucleoside reverse transcriptase translocation inhibitor (NRTTI), a new mechanistic class. Like older nucleoside reverse transcriptase inhibitors (NRTIs) such as emtricitabine or tenofovir, islatravir targets the reverse transcriptase enzyme that HIV uses to convert its RNA into DNA. But it works through a different mechanism.

Older NRTIs work by getting incorporated into the growing viral DNA chain and acting as a chain terminator, stopping DNA synthesis. Islatravir uses this same incorporation mechanism but adds a second layer: after incorporation, its unique 4-ethynyl chemical group physically blocks the reverse transcriptase enzyme from translocating along the template, preventing it from reading the next nucleotide. This dual mechanism, immediate chain termination plus translocation blocking, gives islatravir a higher barrier to resistance than most older NRTIs and a potency-to-dose ratio higher than any currently approved NRTI at comparable concentrations.

An additional pharmacokinetic advantage: islatravir’s active intracellular form (islatravir-triphosphate) has a long intracellular half-life, meaning drug concentrations remain therapeutic even with once-daily dosing and support the possibility of longer-interval formulations now in development.

The Phase 3 Trial Data: What Both Studies Showed

The FDA approval is supported by data from two pivotal Phase 3 trials, both presented at CROI 2025 and CROI 2026, with Week 96 data also available.

	Trial 052 (NCT05630755)	Trial 051 (NCT05631093)
Design	Double-blind, randomized, active-controlled	Open-label, randomized, active-controlled
Comparator	Biktarvy (BIC/FTC/TAF)	Baseline antiretroviral therapy (bART) of any class
Participants (n)	513 adults on Biktarvy	551 adults on various ART regimens
Age 65 or older in combined trials	11% (81 of 708 on Idvynso)	Reflects real-world older patient population
HIV-1 RNA less than 50 copies/mL at Week 48	92% (Idvynso) vs. 94% (BIC/FTC/TAF)	96% (Idvynso) vs. 92% (bART)
Virologic failure (RNA 50 c/mL or higher)	Non-inferior; difference within 4% margin	Idvynso numerically superior; difference 3.6% favoring Idvynso
CD4+ T-cell counts	Stable; no clinically meaningful decline at 0.25 mg dose	Stable in both arms
Weight change at Week 48	0.03 kg decrease (Idvynso) vs. 0.28 kg increase (BIC/FTC/TAF)	0.94 kg increase (Idvynso) vs. 0.15 kg decrease (bART)
Fasting lipids	No clinically meaningful changes vs. comparator	No clinically meaningful changes vs. comparator
HOMA-IR (insulin resistance)	No clinically meaningful effect	No clinically meaningful effect

Source: Merck press release April 21, 2026. CROI 2025 and CROI 2026 late-breaking presentations. NCT05630755, NCT05631093.

The Trial 052 result against Biktarvy is the headline finding. Biktarvy is the most widely prescribed HIV regimen in the world, and demonstrating non-inferiority in a blinded head-to-head trial against it is the most rigorous efficacy test Idvynso could have faced. The 92% vs. 94% suppression rates fall within the pre-specified 4% non-inferiority margin.

The weight data from Trial 052 is particularly notable. In a trial where the comparator is Biktarvy, a minimal weight change with Idvynso (0.03 kg decrease) compared with a slight weight gain with Biktarvy (0.28 kg increase) is a metabolically favorable result, even if the absolute difference is small. For patients already concerned about INSTI-associated weight gain on existing regimens, this data point may influence switching conversations.

Merck presented these results across multiple scientific conferences including CROI 2026 and the European AIDS Conference 2025. The lead investigator characterization of the results at those conferences emphasized the combination of non-inferior virologic suppression and favorable metabolic outcomes as the primary clinical value of the regimen.

The CD4 count history: why the 0.25 mg dose matters Islatravir’s development path was not straightforward. In 2021, the FDA placed clinical holds on several studies of islatravir after decreases in total lymphocyte and CD4+ T-cell counts were observed in some participants. CD4 cells are the immune cells HIV targets, and their count is the primary measure of immune health in people living with HIV. Any drug that reduces CD4 counts independently of HIV control would be clinically unacceptable. Merck’s response was to identify that the CD4 declines occurred at higher doses. The company reformulated the development program around the lower 0.25 mg daily dose used in Idvynso, which in both pivotal trials showed stable CD4 counts comparable to comparator arms. The FDA lifted the holds and the 0.25 mg dose progressed to approval. This history means clinicians prescribing Idvynso should monitor CD4 counts as part of routine follow-up, as specified in the prescribing information. The clinical trial data is reassuring at the approved dose, but ongoing monitoring is appropriate given the earlier signal at higher doses.

Safety Profile: What Patients and Providers Need to Know

Skin reaction warning

Idvynso carries an important precautionary warning regarding severe skin reactions, including Stevens-Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and DRESS syndrome, based on post-marketing experience with doravirine-containing regimens. This is a standard precautionary warning in the prescribing information, not a boxed warning. These reactions are rare but potentially life-threatening. Patients should contact their provider immediately if any rash develops, and stop taking Idvynso if the rash affects mucous membranes (mouth, eyes, genitals) or is accompanied by fever, fatigue, or body aches.

Common side effects

The most common adverse reactions reported in clinical trials are diarrhea, dizziness, fatigue, bloating, headache, and weight gain. Most are low-grade and manageable. The dizziness signal with doravirine is established from prior approvals and is typically mild, occurring most often in the first few weeks of use.

Key drug interactions and contraindications

Strong CYP3A4 inducers: Contraindicated because they significantly decrease doravirine plasma concentrations, which could compromise viral suppression. Common examples include rifampin, carbamazepine, phenytoin, and St. John’s Wort. If a strong CYP3A4 inducer must be used, Idvynso cannot be co-administered.

Lamivudine (3TC) and emtricitabine (FTC): Contraindicated because they significantly decrease islatravir-triphosphate concentrations, directly reducing the antiviral efficacy of the islatravir component. This is a mechanistic interaction: 3TC and FTC compete with islatravir for intracellular phosphorylation.

Rifabutin: Use with caution. May decrease doravirine concentrations; monitor closely if co-administration is necessary.

The lamivudine/emtricitabine contraindication has a practical implication: patients currently on any regimen containing 3TC or FTC (which includes most first-line combinations) need to fully switch to Idvynso as their complete regimen, not add it on top of existing therapy. This is the intended use, but it is worth confirming explicitly in clinical practice.

Dosing, Availability, and Practical Use

Feature	Details
Dose	One tablet (doravirine 100 mg / islatravir 0.25 mg) once daily
Food requirement	Can be taken with or without food
Formulation	Single-tablet; no generic available
Available in pharmacies	From May 11, 2026
Manufacturer	Merck (MSD outside US/Canada)
Indication	Switch regimen for virologically suppressed adults only; not for treatment initiation
Renal impairment	No dose adjustment required (unlike tenofovir-containing regimens)
Hepatic impairment	Use with caution in severe hepatic impairment; see full prescribing information
Pregnancy	Enroll in the Antiretroviral Pregnancy Registry; weigh risks and benefits with provider

Where Idvynso Fits in the HIV Treatment Landscape

Current two-drug HIV regimens approved in the US include dolutegravir/rilpivirine (Juluca) and dolutegravir/lamivudine (Dovato). Both are INSTI-containing. Idvynso is the first two-drug option for virologically suppressed adults that contains neither an INSTI nor tenofovir.

For clinicians managing patients with INSTI-associated weight gain or metabolic concerns, or patients with renal considerations where tenofovir management is complex, Idvynso adds a new conversation to the switching discussion. For patients, the availability of a single tablet, taken with or without food, with no tenofovir and no INSTI, backed by head-to-head data against the most widely prescribed HIV regimen in the world, is a meaningful new option.

Islatravir’s approval as part of Idvynso also opens clinical experience with the NRTTI class that will inform the development of longer-interval formulations. Merck has a monthly oral islatravir program in development and a long-acting injectable combination in earlier stages. The twice-yearly injectable lenacapavir (Sunlenca), approved for heavily treatment-experienced patients, has already demonstrated that very long dosing intervals are achievable in HIV treatment. The trajectory for people with HIV is toward fewer doses, fewer pills, and longer intervals, and Idvynso is one step on that path.

For context on how the FDA’s CNPV program has been used to accelerate approvals for other conditions in 2026, see our post on the FDA’s fast-tracking of psychedelic drug programs for mental illness and our coverage of the first gene therapy for deafness approved under the same program.

Are you living with HIV and considering a switch?

Whether Idvynso is right for you depends on your full treatment history, current regimen, resistance testing results, and individual health considerations. This conversation belongs with an HIV specialist or an infectious disease provider experienced in antiretroviral therapy. The Ryan White HIV/AIDS Program site finder can help connect patients to specialized HIV care. HIV.gov also maintains a testing and care site locator. For complete prescribing information, Merck’s full prescribing information is available here.

Sources

FDA approval / Merck press release: FDA Approves Merck’s Once-Daily IDVYNSO (doravirine/islatravir). April 21, 2026.

Pharmacy Times: FDA Approves Once-Daily HIV Regimen Combining Doravirine and Islatravir. pharmacytimes.com. April 2026.

Drugs.com approval history: Idvynso (doravirine and islatravir) FDA Approval History. drugs.com.

Drugs.com drug information: Idvynso: Uses, Dosage, Side Effects and Warnings. drugs.com.

Merck CROI 2026 data: Merck Announces Late-Breaking Data from Three Phase 3 Trials at CROI 2026. merck.com. February 25, 2026.

Merck European AIDS Conference data (weight/metabolic): Merck Announces New Data from Phase 3 Trials at European AIDS Conference. merck.com. October 2025.

PharmExec: FDA Approves Idvynso for Treatment of HIV-1 Infection in Adults. pharmexec.com.

EATG press release summary: FDA approves Merck’s Once-Daily IDVYNSO (doravirine/islatravir). eatg.org. April 2026.

Islatravir mechanism (PubMed): Islatravir has a high barrier to resistance and exhibits a differentiated resistance profile. PubMed PMID 35546110.

Idvynso prescribing information: IDVYNSO (doravirine/islatravir) Full Prescribing Information. Merck. April 2026.

Trial 052 registration: NCT05630755. A Switch to Doravirine/Islatravir in Participants Virologically Suppressed on BIC/FTC/TAF. ClinicalTrials.gov.

Trial 051 registration: NCT05631093. A Switch to Doravirine/Islatravir in Participants Virologically Suppressed on ART. ClinicalTrials.gov.

Disclaimer: Health Evidence Digest provides general information about FDA approvals and health research for educational purposes. This content is not a substitute for professional medical advice. HIV treatment decisions, including switching antiretroviral regimens, should be made in close consultation with a qualified HIV specialist or infectious disease provider familiar with your full treatment history and resistance profile.

May 16, 2026

A New Device for Detecting Uterine Cancer in the Doctor’s Office Just Received FDA Clearance. Here Is Who Should Know About It.

Uterine cancer is the most common gynecologic malignancy in the United States. This year, an estimated 68,270 women will receive a new diagnosis of endometrial carcinoma, the most common type. Death rates from the disease have been rising steadily since 1997, and the gap between early-stage survival (up to 95%) and late-stage survival (below 20%) is among the widest of any cancer. The difference between those two outcomes often comes down to whether the cancer was caught before it spread.

Unlike cervical cancer, which has a well-established routine screening test (the Pap smear), endometrial cancer has no recommended population-level screening for average-risk women. Diagnosis depends on evaluating symptoms, primarily abnormal uterine bleeding, and performing an endometrial biopsy when warranted. The current standard device for that biopsy is the Pipelle sampler, a thin plastic catheter that has not fundamentally changed in decades.

On April 22, 2026, Utepreva LLC announced FDA 510(k) clearance for the Utepreva Endometrial Sampler, a redesigned single-use device that combines three collection mechanisms in one instrument and supports cytologic, histopathologic, and molecular testing from a single sample. The company says the procedure takes about 20 seconds and requires no dilation, sedation, or operating room. Providers can order it beginning in October 2026.

Endometrial Cancer: The Disease Most Women Know Least About

The endometrium is the inner lining of the uterus. Each month during a woman’s reproductive years, it thickens in preparation for a potential pregnancy and sheds if conception does not occur. When cells in this lining undergo malignant transformation, the result is endometrial carcinoma, the most common uterine cancer by far.

Most endometrial cancers are diagnosed because a woman reports abnormal uterine bleeding to her gynecologist. In postmenopausal women, any vaginal bleeding is considered abnormal and warrants evaluation. Because this symptom tends to appear when the cancer is still localized to the uterus, endometrial cancer is frequently caught at stage I, when surgical removal is usually curative. The problem is the proportion of women who either dismiss the bleeding, delay seeking care, or are told it is nothing to worry about before receiving a proper evaluation.

The racial disparity in endometrial cancer outcomes Non-Hispanic Black women have the highest mortality rate from uterine cancer of any racial or ethnic group in the United States, and the gap has been widening. Black women are more likely to be diagnosed with aggressive non-endometrioid histologic subtypes (Type II tumors), which account for a disproportionate share of deaths despite representing a minority of total cases. Barriers to timely evaluation, lower rates of specialist access, and differences in tumor biology all contribute. Any advance in detection infrastructure that makes endometrial evaluation faster, less costly, and more accessible in office-based settings has equity implications as well as clinical ones.

Who Is at Risk: A Practical Guide to Endometrial Cancer Risk Factors

Most endometrial cancer risk comes down to one underlying mechanism: prolonged exposure of the uterine lining to estrogen without the counterbalancing effect of progesterone. Conditions that increase this “unopposed estrogen” exposure elevate endometrial cancer risk. Here is what that looks like in practice.

Risk factor	What it means clinically
Postmenopausal bleeding	The most actionable symptom. Any vaginal bleeding after menopause requires evaluation. This alone is an indication for endometrial sampling regardless of other risk factors.
Obesity (BMI 30 or above)	The strongest modifiable risk factor. Excess body fat increases peripheral conversion of androgens to estrogen. Nearly 70% of early-stage endometrial cancer patients are obese.
Estrogen therapy without progestogen	Women with a uterus taking estrogen-only hormone therapy have significantly elevated risk. Combination (estrogen plus progestogen) therapy does not carry the same risk.
Tamoxifen use	Tamoxifen, used in breast cancer treatment and prevention, acts as an estrogen agonist in the uterus even while blocking estrogen in breast tissue. Women on tamoxifen who develop any abnormal uterine bleeding should be evaluated promptly.
Lynch syndrome (hereditary)	Lynch syndrome carriers have a lifetime endometrial cancer risk of 13 to 60%, depending on the gene mutation (MLH1, MSH2, MSH6, PMS2). This is often higher than their colorectal cancer risk. All women with Lynch syndrome should discuss surveillance with their gynecologist.
Nulliparity and late menopause	Women who have never been pregnant and those who experienced menopause after age 55 have had longer cumulative estrogen exposure.
Diabetes and metabolic syndrome	Hyperinsulinemia and insulin resistance promote endometrial cell proliferation independently of estrogen levels.
Age 50 to 70	Incidence peaks in this age range, coinciding with the postmenopausal transition and its associated hormonal changes.
Family history	A first-degree relative with endometrial or colorectal cancer warrants discussion about Lynch syndrome testing even if the patient does not meet formal criteria.

Sources: AAFP (Am Fam Physician. 2025;111(6):526-531), StatPearls Endometrial Cancer, StatPearls Postmenopausal Bleeding.

How Endometrial Cancer Is Currently Diagnosed

When a woman presents with postmenopausal bleeding or other concerning symptoms, the standard evaluation pathway begins with a pelvic examination and often a transvaginal ultrasound to measure endometrial thickness. An endometrial stripe of more than 4 mm in a postmenopausal woman with bleeding is an indication for tissue sampling. Even a stripe below that threshold does not rule out malignancy if bleeding is persistent.

Tissue sampling is performed with an endometrial sampler inserted through the cervix into the uterine cavity. The Pipelle sampler, introduced in the 1980s, remains the most commonly used device in the United States. It is a thin plastic catheter that uses a retractable piston to create suction and aspirate endometrial tissue. It works well in straightforward cases but has documented limitations: it samples a fraction of the uterine cavity, may produce insufficient tissue in certain uterine configurations, and cannot collect the range of sample types (cytologic, histopathologic, molecular) from a single pass that modern testing increasingly requires.

When the Pipelle yields insufficient tissue, or when a focal lesion is suspected, the next step is dilation and curettage (D&C) under sedation or general anesthesia, with or without hysteroscopy. This requires operating room resources, carries anesthesia risk, and adds cost and scheduling delay.

🔗 Also on HED: Vaginal Estrogen Safety in Endometrial Cancer Survivors Our previous post covered a landmark 2,824-patient matched cohort study and the FDA’s February 2026 removal of the boxed warning for vaginal estrogen in endometrial cancer survivors. Relevant background for anyone following uterine cancer care
https://healthevidencedigest.com/vaginal-estrogen-therapy-not-linked-to-cancer-recurrence-in-younger-survivors-of-endometrial-cancer/

What the Utepreva Endometrial Sampler Is and How It Works

The Utepreva Endometrial Sampler (510(k) clearance K240595) is a single-use, patented device that combines three distinct tissue collection mechanisms in one instrument, intended to be performed as a single-pass sampling procedure.

The three mechanisms

Tissue disruption (brush): A brush component at the device tip physically disrupts the endometrial surface to loosen tissue, similar in concept to how a cervical brush works in a Pap smear.
Suction (plunger-driven aspiration): A plunger inside the sheath generates suction that aspirates dislodged cells and tissue into the collection channel, preventing sample loss. This replaces the piston-retraction mechanism of the Pipelle with a more controlled aspiration system.
Sponge absorption: A sponge tip at the device end absorbs fluid and cells from the uterine cavity. This captures material that would not be collected by suction alone, including cells suspended in uterine fluid rather than adherent to the wall.

The device features a slim-profile wand and an integrated cervical guard to prevent over-insertion. The company states the procedure is completed in approximately 20 seconds, requires no cervical dilation, no sedation, and no operating room.

What types of testing the sample supports

Because the device collects tissue through three complementary mechanisms, the resulting sample supports three categories of laboratory analysis from a single collection pass:

Cytologic analysis: examination of individual cells and cell clusters under a microscope, comparable to cervical cytology in a Pap smear.
Histopathologic analysis: examination of tissue architecture and cell morphology in the standard endometrial biopsy format, allowing diagnosis of endometrial hyperplasia, atypical hyperplasia, and carcinoma.
Molecular analysis: biomarker testing including mismatch repair protein immunohistochemistry, Lynch syndrome screening, and other emerging molecular markers that increasingly inform endometrial cancer subtyping and treatment planning.

Artera notes that results are available within one to two days and that the test produces no inconclusive results based on insufficient tissue, which is a relevant distinction: one of the main failpoints of the current Pipelle is producing an insufficient sample that requires a return visit or D&C.

The Preclinical Evidence: What Testing Showed

The FDA clearance was supported by preclinical and design verification testing conducted by Medical Murray, a medical device manufacturer. Testing compared the Utepreva device against a commercially available endometrial sampler using a standardized model of simulated endometrial tissue under controlled conditions.

Under those conditions, the Utepreva device captured a greater volume of simulated tissue and demonstrated more uniform disruption across the sampling surface. The difference in tissue capture was statistically significant. The company has presented the device at the American College of Obstetricians and Gynecologists Annual Clinical and Scientific Meeting in May 2026.

What the clearance pathway tells us about the evidence standard The FDA cleared Utepreva through the 510(k) pathway, which permits clearance of a medical device if it is substantially equivalent to an already legally marketed device. The Utepreva Endometrial Sampler is substantially equivalent to existing endometrial sampling devices, cleared for the same intended use, which is obtaining endometrial tissue samples for laboratory analysis. 510(k) clearance does not require the same level of clinical efficacy evidence as a PMA (premarket approval) or a drug NDA. The supporting data is preclinical bench testing, not randomized clinical trials in patients. This means the device’s performance in real clinical settings, across diverse patient populations and uterine anatomies, will need to be established through post-clearance use and publication. The absence of peer-reviewed clinical trial data at the time of clearance is a standard feature of most new medical device clearances, not a red flag specific to Utepreva. It is, however, a limitation worth naming clearly for anyone following this device’s evidence trajectory.

What Patients Should Know: Who Needs Endometrial Evaluation and When

There is no routine screening test for average-risk women

Current guidelines from AAFP, ACOG, and the American Cancer Society do not recommend routine endometrial cancer screening in asymptomatic women at average risk. No Pap smear equivalent exists for the endometrium. This means that for most women, the pathway to early diagnosis runs through symptom recognition and timely evaluation, not through a scheduled test.

Report any postmenopausal bleeding promptly

Postmenopausal bleeding is the reason for approximately two-thirds of all gynecologic office visits in postmenopausal women, and it is the single most important early symptom of endometrial cancer. Any bleeding after 12 consecutive months without a period warrants a same-cycle evaluation rather than a wait-and-see approach. Even a single episode of light spotting should be discussed with a gynecologist.

Special situations that warrant proactive discussion

Women with Lynch syndrome should discuss an individualized surveillance plan with their gynecologist. Annual endometrial sampling beginning at age 30 to 35 is considered for Lynch carriers in some guidelines, though the evidence base for specific protocols remains limited.
Women taking tamoxifen should be counseled on endometrial cancer symptoms at each follow-up visit. Any abnormal uterine bleeding should trigger evaluation, even if the ovaries are still functioning.
Women with obesity who are approaching or in the menopause transition have enough baseline risk that any menstrual irregularity outside a normal perimenopause pattern warrants discussion with a provider rather than dismissal.

When will Utepreva be available?

Utepreva LLC has announced the device will be available to healthcare providers beginning in October 2026. Patients will not purchase or use it directly. If your gynecologist performs endometrial sampling in the office, you can ask whether they will be adopting the new device. For now, the Pipelle and similar existing samplers remain the standard of care for in-office endometrial biopsy.

The bottom line

Endometrial cancer is the most common gynecologic cancer in the United States, and it is one where early detection reliably leads to good outcomes. The current diagnostic infrastructure relies on a device that has not been meaningfully updated in decades, and on patients and providers taking postmenopausal bleeding seriously at first presentation. The Utepreva Endometrial Sampler does not change who needs evaluation or when. What it offers, if its preclinical performance translates to clinical practice, is a more comprehensive tissue sample from a single office procedure. Real-world clinical data after the October 2026 launch will determine whether the promise holds. For patients and providers navigating this space today, the most useful resources remain ACOG’s clinical practice guidelines on endometrial cancer evaluation and the American Cancer Society’s endometrial cancer overview.

Sources

Utepreva press release (PR Newswire): Utepreva Introduces FDA 510(k)-Cleared Endometrial Sampler Designed to Support Early Detection of Endometrial Cancer. April 22, 2026.

Contemporary OB/GYN: Utepreva Launches FDA-Cleared Endometrial Sampler to Support Endometrial Cancer Detection. contemporaryobgyn.net. April 2026.

Clinical Lab Products: New Endometrial Sampling Device Receives FDA Clearance for Cancer Detection. clpmag.com. April 2026.

BioSpace: Utepreva Introduces FDA 510(k)-Cleared Endometrial Sampler. biospace.com. April 22, 2026.

FDA 510(k) clearance record: Utepreva Endometrial Sampler (UP01), K240595. FDA.gov.

AAFP Rapid Evidence Review: Endometrial Cancer. Am Fam Physician. 2025;111(6):526-531.

StatPearls (endometrial cancer): Endometrial Cancer. StatPearls. NCBI Bookshelf. Updated 2024.

StatPearls (postmenopausal bleeding): Postmenopausal Bleeding. StatPearls. NCBI Bookshelf. Updated January 2025.

Medscape: Endometrial Carcinoma: Background, Etiology, Epidemiology. emedicine.medscape.com.

ACS uterine cancer statistics: Key Statistics for Uterine Cancer. cancer.org.

HED internal: Vaginal Estrogen Safety in Endometrial Cancer Survivors and the FDA February 2026 Boxed Warning Removal. Health Evidence Digest.

Disclaimer: Health Evidence Digest provides general information about medical devices and health research for educational purposes. This content is not a substitute for professional medical advice. The Utepreva Endometrial Sampler is a cleared medical device, not a diagnostic test or treatment. All decisions about endometrial evaluation and cancer screening should be made in consultation with a qualified gynecologist or healthcare provider.

May 14, 2026

A New AI Tool Can Help Predict Which Breast Cancer Patients Can Skip Chemotherapy. The FDA Just Cleared It.

Chemotherapy works. For many women with breast cancer, it meaningfully reduces the risk that cancer will return. But chemotherapy also causes real harm: nausea, fatigue, increased infection risk, potential cardiac effects, nerve damage, and in some cases long-term consequences that persist years after treatment ends. For decades, oncologists have known that some women with early-stage breast cancer receive chemotherapy even though their tumor biology would never have threatened them with a recurrence. They endure months of treatment and its side effects for a benefit that, statistically, would not have materialized.

The challenge has always been identifying those women reliably, at the time of diagnosis, before any treatment has started. Existing tools like Oncotype DX and MammaPrint already attempt this, but they require separate molecular testing, come with turnaround times of several days, and cost thousands of dollars. The question the field has been working toward: can AI read a standard pathology slide, combine that with basic clinical data, and produce reliable risk stratification at the point of diagnosis, using materials that already exist?

On May 6, 2026, the FDA cleared ArteraAI Breast (Artera) for exactly that purpose. It is the first FDA-cleared digital pathology-based risk stratification tool for breast cancer. The answer, based on validated clinical trial data, is yes.

🔗 Also on HED: AI-Supported Mammography Just Got Its Strongest Evidence Yet This post is part of an ongoing HED series on artificial intelligence in women’s cancer care. Our previous post covered the landmark MASAI trial, which showed AI-supported mammography detected more cancers with no increase in false positives in a 105,000-woman randomized controlled trial.

Who ArteraAI Breast Is For

ArteraAI Breast is cleared for patients with early-stage, hormone receptor-positive (HR+), HER2-negative invasive breast cancer. This is the most common breast cancer subtype, accounting for approximately 70% of all breast cancer diagnoses. The HR+/HER2- designation means the tumor is driven by estrogen or progesterone signaling and does not overexpress HER2. Standard treatment for early-stage disease in this group includes surgery, radiation, endocrine therapy (hormonal treatment), and, depending on risk, chemotherapy.

The decision about whether to add chemotherapy to endocrine therapy is the key clinical question for most of these patients. Women with clearly high-risk tumors, based on size, lymph node involvement, and grade, typically receive chemotherapy. Women with clearly low-risk disease typically receive endocrine therapy alone. But a substantial middle group sits in ambiguous territory, where the right answer is not obvious from standard pathological features alone. This is precisely the population ArteraAI Breast is designed to help.

How ArteraAI Breast Works

The tool uses multimodal artificial intelligence (MMAI), a term that describes AI systems that combine multiple types of data rather than analyzing a single input. In this case, the two inputs are a digitized histopathology image and patient clinical variables.

The pathology slide input

When a breast tumor is surgically removed, tissue samples are processed, embedded in paraffin wax, sliced very thin, stained with standard dyes (hematoxylin and eosin, or H&E), and placed on glass slides. A pathologist reviews these slides under a microscope to assess tumor grade, cell type, and other features. For ArteraAI Breast, the same slides are digitally scanned at high resolution, creating whole-slide images that the AI analyzes. No additional staining, no additional tissue processing, and no additional cost for sample preparation.

The clinical variables input

Alongside the digitized image, the system incorporates standard patient clinical data such as age, tumor size, nodal status, and grade. This multimodal approach allows the AI to recognize patterns across both the visual features of the tumor tissue and the clinical context, producing a composite risk score that neither input alone could generate as accurately.

The output

ArteraAI Breast generates a numerical risk score that provides prognostic information on the likelihood of distant metastasis. Using a predefined risk score cutoff, patients are stratified into low-risk and high-risk groups. Artera reports that results are available within one to two days of receiving the digitized sample, and the test produces no inconclusive results based on insufficient tissue, which is a meaningful practical advantage over some existing molecular assays.

How does this differ from Oncotype DX and MammaPrint? Oncotype DX (Genomic Health/Exact Sciences) and MammaPrint (Agendia) are the two most widely used molecular risk stratification tests for early-stage HR+/HER2- breast cancer. Both analyze gene expression patterns in tumor tissue and generate recurrence risk scores. Both are validated in large clinical trials (TAILORx for Oncotype DX, MINDACT for MammaPrint) and incorporated into NCCN and ASCO guidelines. The key practical differences with ArteraAI Breast are the input type and the infrastructure required. Oncotype DX and MammaPrint require tumor tissue to be processed with specialized molecular assays, shipped to central laboratories, and analyzed using RNA extraction and gene expression profiling. This adds cost, processing time, and requires specific tissue handling. ArteraAI Breast uses the standard H&E pathology slides that every pathology laboratory already produces as part of routine diagnosis, digitized on equipment increasingly common in pathology labs. ArteraAI Breast does not yet have the decades of clinical validation data behind Oncotype DX and MammaPrint. The tools serve complementary rather than competing roles in the current clinical framework. As the evidence base for ArteraAI grows, the field will develop clearer guidance on how these tools should be used together or sequentially.

The Clinical Trial Data Behind the Clearance

The FDA clearance is supported by data from two clinical trials, both presented at the 2025 San Antonio Breast Cancer Symposium (SABCS).

ABCSG 8 trial: postmenopausal patients, 10-year outcomes

In a presentation evaluating postmenopausal patients from the ABCSG 8 trial (NCT00291759), the MMAI platform stratified patients into three risk groups with the following 10-year distant metastasis-free survival rates:

Risk group	10-year DMFS	Clinical meaning
Low risk	Approximately 95%	Very low likelihood of cancer spreading to distant organs within 10 years
Intermediate risk	Approximately 89%	Moderate likelihood; additional therapy discussion warranted
High risk	Approximately 77%	Substantially elevated risk; chemotherapy benefit more likely to outweigh harm

NSABP B-20 trial: chemotherapy benefit in high-risk patients

A separate presentation evaluated patients with node-negative, HR-positive disease from the NSABP B-20 trial. In the subset of patients the MMAI tool classified as high-risk, chemotherapy produced a 52% relative decrease in 10-year distant metastasis rates compared with no chemotherapy. This is the predictive component of the tool: not just identifying who has high recurrence risk, but identifying who actually benefits from adding chemotherapy.

The 52% figure is clinically significant. It suggests the AI is not merely sorting patients by overall risk level but identifying the biologically distinct group for whom chemotherapy’s mechanism of action provides substantial additional protection beyond endocrine therapy alone.

Both datasets were presented at SABCS 2025 rather than published in a peer-reviewed journal at the time of FDA clearance. Peer-reviewed publication of the full analyses will be an important milestone for establishing this tool’s position in clinical guidelines.

“Patients and clinicians need to understand their risks for recurrence and decide which treatments will be the most effective, thereby avoiding both undertreatment and overtreatment.” — Calvin Chao, MD, Vice President of Medical Science, Artera. Medical News Today, May 2026.

The Bigger Picture: AI Is Changing How Oncologists Make Treatment Decisions

ArteraAI Breast is part of a broader pattern in oncology: artificial intelligence tools are moving from research into regulated clinical practice, with specific cleared or approved uses that change how clinicians gather and act on diagnostic information. The FDA clearance for ArteraAI Breast came in the same month as several other landmark AI decisions in women’s health, reflecting a maturation of the regulatory pathway for these tools.

The clinical and societal significance of AI in this specific context is worth stating plainly. Approximately 300,000 women are diagnosed with breast cancer in the United States each year. A substantial fraction have early-stage HR+/HER2- disease, the exact population for whom the chemotherapy decision is genuinely uncertain. Any tool that reliably identifies the women who can safely avoid chemotherapy reduces harm at scale, not just for individual patients.

The challenge the field now faces is integration. Hospitals need digital pathology scanning infrastructure. Clinicians need to understand what the score means and how to incorporate it alongside existing tools. Guidelines from NCCN, ASCO, and other bodies will need to address how ArteraAI fits alongside Oncotype DX and MammaPrint in clinical decision-making. None of this happens automatically after FDA clearance.

What Patients with Early-Stage HR+/HER2- Breast Cancer Should Know

Is this tool available at my hospital?

ArteraAI Breast received FDA clearance on May 6, 2026. Commercial availability is being rolled out now. Not every hospital or pathology laboratory will have access immediately. Availability depends on whether the institution has digital pathology scanning capability and whether they have contracted with Artera. It is reasonable to ask your oncologist or breast surgeon whether their center uses ArteraAI or a similar digital pathology tool.

Does this replace Oncotype DX or other genomic tests?

Not currently. Oncotype DX and MammaPrint have more extensive published evidence and are incorporated into major clinical guidelines. ArteraAI Breast is a new cleared tool with promising validation data. The two types of tests are based on different biological signals and may provide complementary information. Your oncologist will determine which risk stratification approach is most appropriate for your specific situation.

What does a low-risk result mean in practice?

A low-risk score from ArteraAI Breast indicates that the tumor’s pathological features and your clinical characteristics, as analyzed by the AI, suggest a low probability of distant metastasis. It does not guarantee that cancer will not return. What it does provide is additional evidence that can inform the conversation with your oncologist about whether chemotherapy is likely to offer you a meaningful benefit. That conversation still requires individual clinical judgment, not just a test result.

What limitations exist?

The supporting data was presented at a conference, not yet published in a peer-reviewed journal. Peer-reviewed publication with full methodology and statistical detail is the standard against which tools are evaluated by guidelines committees. This is expected to follow, and the FDA clearance was granted on the basis of this data, but it is a relevant caveat.
The tool stratifies into low and high risk, not a single continuous recurrence score. Some other tools provide a continuous score with a range of risk thresholds. The binary or three-tier stratification provides clear decision support but may not capture the full spectrum of risk for every individual patient.
Long-term prospective data specifically tracking ArteraAI-guided treatment decisions and their outcomes does not yet exist. The existing validation uses retrospective data from prior trials. Prospective evidence that patients guided by ArteraAI scores have better outcomes than those guided by standard assessment alone will take time to accumulate.

The bottom line

For a large number of women with early-stage HR+/HER2- breast cancer, chemotherapy is a treatment they could safely skip. Identifying those women reliably at diagnosis has always been the challenge. ArteraAI Breast is a new, FDA-cleared tool that uses the pathology slide already generated during standard cancer diagnosis to produce a risk score within one to two days, with no additional tissue processing required. The clinical trial data supporting the clearance is promising, particularly the 52% reduction in distant metastasis with chemotherapy in the tool’s high-risk group. The limitations around peer-reviewed publication and prospective outcome data are real and worth tracking. For patients currently navigating a breast cancer diagnosis, the most useful next step is a conversation with a breast oncologist about which risk stratification tools are appropriate for your specific tumor and clinical profile. The National Cancer Institute Cancer Center directory and the Susan G. Komen helpline are strong starting points for connecting with specialized breast oncology care.

Sources

Artera FDA clearance press release: Artera Receives U.S. FDA Clearance for ArteraAI Breast, Expanding Its AI Platform to Breast Cancer. May 6, 2026.

CancerNetwork: FDA Clears AI Stratification Tool in HR+/HER2- Invasive Breast Cancer. CancerNetwork. May 2026.

ITN Online: FDA Clears AI Digital Pathology Risk Stratification Tool in Breast Cancer. Imaging Technology News. May 6, 2026.

Femtech Insider: Artera Receives FDA Clearance for AI-Powered Breast Cancer Risk Stratification Tool. Femtech Insider. 2026.

Medical News Today: FDA-cleared AI risk tool could help guide breast cancer therapy. Medical News Today. May 2026.

Medical Device Network: Artera hits US first with pathology-based breast cancer risk tool’s clearance. May 2026.

BusinessWire: Artera Receives U.S. FDA Clearance for ArteraAI Breast. BusinessWire. May 6, 2026.

LabMedica: FDA Clears AI Digital Pathology Tool for Breast Cancer Risk Stratification. LabMedica. 2026.

ABCSG 8 trial: Austrian Breast and Colorectal Cancer Study Group Trial 8 (NCT00291759).

NSABP B-20 trial: National Surgical Adjuvant Breast and Bowel Project B-20. ClinicalTrials.gov.

HED internal post (MASAI): AI-Supported Mammography Just Got Its Strongest Evidence Yet. Health Evidence Digest.

Disclaimer: Health Evidence Digest provides general information about FDA clearances and health research for educational purposes. This content is not a substitute for professional medical advice. ArteraAI Breast is a risk stratification aid and is not intended to replace clinical judgment. All treatment decisions for breast cancer should be made in consultation with a qualified oncologist.

May 13, 2026

For the First Time, Every Form of Myasthenia Gravis Has an Approved Treatment. What the FDA’s May 8 Decision Means for Patients Who Were Left Out.

📌 The essentials On May 8, 2026, the FDA approved a label expansion for VYVGART (efgartigimod alfa-fcab, IV infusion) and VYVGART Hytrulo (efgartigimod alfa and hyaluronidase-qvfc, subcutaneous injection), making them the first and only FDA-approved treatments for ALL serotypes of adult generalized myasthenia gravis (gMG), including anti-AChR antibody positive (previously covered), anti-MuSK antibody positive (newly covered), anti-LRP4 antibody positive (newly covered, first approved therapy ever for this subtype), and triple seronegative (newly covered, first approved therapy ever for this subtype). The clinical basis: The Phase 3 ADAPT SERON trial (NCT06298552), the largest clinical study ever conducted specifically in seronegative gMG, met its primary endpoint with statistical significance (p=0.0068), showing a mean 3.35-point improvement in the MG-ADL (Activities of Daily Living) score at week 4 compared to placebo. Who this matters most for: The approximately 20% of gMG patients whose antibody tests come back negative, a population that has been systematically excluded from clinical trials and left with no indication-specific approved therapy until today.

If you have been diagnosed with myasthenia gravis but your antibody test came back negative, you already know what it means to be told your disease is real while the treatment options designed around your specific diagnosis are not. Until May 8, 2026, no FDA-approved therapy carried an indication that specifically covered your form of the disease. That changed today.

Generalized myasthenia gravis (gMG) is a rare, chronic autoimmune disease of the neuromuscular junction, the connection point between nerve signals and muscle movement. When it malfunctions, the result is debilitating muscle weakness that can affect the ability to breathe, swallow, speak, see clearly, or move. For roughly 80% of patients, the diagnosis is confirmed by a blood test that detects antibodies against the acetylcholine receptor (AChR-Ab). For the remaining 20%, those tests come back negative or detect antibodies against different targets entirely.

That 20% has historically been a clinical blind spot: rarely included in the pivotal trials that generate approved indications, often managed with the same medications as antibody-positive patients but without the evidence base to support that approach formally, and excluded from having a therapy with their specific diagnosis on the label. The May 8 expansion closes that gap.

What Myasthenia Gravis Is and Why Serotype Matters

Myasthenia gravis is caused by pathogenic immunoglobulin G (IgG) antibodies that attack proteins at the neuromuscular junction, disrupting the transmission of nerve signals to muscles. The specific protein being attacked determines the serotype, and different serotypes can produce somewhat different clinical presentations.

gMG Serotype	Target antibody	Prevalence in gMG	Pre-May 8 approved therapy with specific indication
Anti-AChR antibody positive	Acetylcholine receptor	~80% of gMG patients	Yes (multiple approved therapies)
Anti-MuSK antibody positive	Muscle-specific tyrosine kinase	~1 to 10% of gMG patients	None specific to this serotype
Anti-LRP4 antibody positive	Low-density lipoprotein receptor-related protein 4	~1 to 5% of gMG patients	None, ever
Triple seronegative	No detectable AChR, MuSK, or LRP4 antibodies	~10% of gMG patients	None, ever

The practical implications of serotype extend beyond treatment options. Triple seronegative patients historically have faced a longer and more complicated path to diagnosis because the standard antibody tests that confirm MG in most patients simply don’t help in their case. Diagnosis relies on clinical presentation, electrodiagnostic testing (repetitive nerve stimulation, single-fiber EMG), and expert clinical judgment. This difficulty getting to a confirmed diagnosis is part of why these patients have also been harder to enroll in clinical trials, which has in turn meant fewer trials designed to study them. It is a reinforcing cycle that the ADAPT SERON trial was specifically designed to break.

gMG as a Women’s Health Issue: Why This Approval Matters by Gender

Myasthenia gravis has a bimodal age distribution. In women, it peaks in the third and fourth decades of life, with women under 40 representing the highest-prevalence group in this earlier peak. This matters because the women most likely to be diagnosed with gMG are also in their reproductive years, and the intersection of this disease with pregnancy is clinically significant and underrecognized in mainstream health coverage.

gMG can worsen during pregnancy. The physiological changes of pregnancy, including shifts in immune regulation, can affect disease activity in either direction, but exacerbation during pregnancy is well documented and requires careful co-management with neurology and maternal-fetal medicine. Importantly, gMG can cause neonatal myasthenia gravis in newborns: maternal antibodies cross the placenta and temporarily affect the newborn’s neuromuscular function, causing transient muscle weakness, feeding difficulties, and in severe cases, respiratory compromise. Neonatal MG typically resolves as maternal antibodies are cleared, but it requires neonatal monitoring and sometimes intervention.

For women with seronegative gMG in particular, pregnancy planning has been especially complex because of the lack of approved options with a safety and efficacy record in their specific form of the disease. The VYVGART label includes a pregnancy exposure registry (VYVGARTPregnancy.com, 1-855-272-6524), and the prescribing information notes that it is not known whether VYVGART or VYVGART Hytrulo will harm an unborn baby. This should be a direct conversation between patients and their neurologist before and during pregnancy planning.

For women navigating other autoimmune conditions alongside reproductive health decisions, our post on GLP-1 medications and PCOS fertility research addresses a similar intersection of systemic disease management and reproductive planning.

The Mechanism: What Is an FcRn Blocker and Why Does It Work Across All Serotypes?

To understand why efgartigimod works regardless of which antibody is causing the disease, it helps to understand the biology it targets.

In gMG, the damaging agents are IgG autoantibodies. The specific target those antibodies attack determines the serotype. A drug designed to block AChR-Ab specifically (like eculizumab, which targets complement downstream of AChR-Ab) or MuSK-Ab specifically will only help patients with those particular antibodies. This target-specific approach is why earlier approved therapies couldn’t cover all serotypes: they worked downstream of one antibody type, not upstream of all of them.

Efgartigimod takes a fundamentally different approach. Rather than blocking a specific pathogenic antibody, it reduces the total circulating pool of all IgG antibodies, including the pathogenic ones, regardless of which protein they are targeting.

The FcRn pathway

FcRn (neonatal Fc receptor) is a protein expressed in many cell types throughout the body. Its normal function is to protect IgG antibodies from degradation, extending their half-life in circulation. When an IgG antibody is taken up by a cell, FcRn binds to it in the endosome and recycles it back to the cell surface, releasing it back into circulation rather than allowing it to be degraded. This recycling mechanism is why IgG antibodies have such long half-lives compared to other proteins.

Efgartigimod is an engineered fragment of a human IgG1 antibody that binds to FcRn with high affinity. By occupying FcRn, it competes with endogenous IgG antibodies for receptor binding. IgG antibodies that cannot bind FcRn during the recycling process are instead routed to degradation. The result is a significant reduction in total circulating IgG levels, including the pathogenic IgG autoantibodies responsible for gMG across all serotypes.

Because this mechanism does not depend on which specific IgG antibody is causing the disease, it works whether the target is AChR, MuSK, LRP4, or an antibody that hasn’t been identified yet. This is why the ADAPT SERON trial showed improvements across all three previously excluded serotypes, and why the FDA’s label expansion covers all adult gMG patients rather than requiring serotype-specific subgroup analysis to drive the approval.

How efgartigimod compares mechanistically to other approved gMG treatments Prior to this approval, the main classes of approved or widely used therapies for gMG worked through different and more targeted mechanisms. Acetylcholinesterase inhibitors (pyridostigmine/Mestinon) don’t address the autoimmune cause at all; they work by slowing acetylcholine breakdown at the NMJ to compensate for the reduced receptor availability. Corticosteroids and general immunosuppressants (azathioprine, mycophenolate) broadly suppress the immune system, which reduces antibody production but also carries long-term systemic effects. Complement inhibitors (eculizumab/Soliris, ravulizumab/Ultomiris) target the complement pathway that AChR antibodies activate, which is why they work in anti-AChR positive patients but not in MuSK or seronegative patients, where complement is not the primary mechanism of damage. B-cell depleting therapies (rituximab, used off-label in MuSK-positive disease) work by eliminating the B cells that produce pathogenic antibodies, which can be particularly effective in MuSK-positive disease but requires significant immunosuppression. FcRn blockade with efgartigimod works upstream of all of these mechanisms, directly depleting the pathogenic antibodies themselves rather than compensating for their effects or blocking their downstream consequences.

The ADAPT SERON Trial: What the Evidence Shows

Trial design

ADAPT SERON (NCT06298552) was a randomized, double-blind, placebo-controlled, multicenter Phase 3 study, conducted across North America, Europe, China, and the Middle East. It enrolled 119 adults with anti-AChR antibody negative gMG, spanning all three seronegative serotypes: anti-MuSK antibody positive, anti-LRP4 antibody positive, and triple seronegative.

This was the largest clinical trial ever conducted specifically in seronegative gMG. Every enrolled participant had a confirmed MG diagnosis verified by an independent panel of experts and an MG-ADL total score of 5 or higher at enrollment, indicating meaningful functional impairment. Participants were on stable background therapy prior to randomization, including acetylcholinesterase inhibitors, corticosteroids, or other immunosuppressive drugs.

Part A of the study randomized participants 1:1 to receive either 4 once-weekly IV infusions of efgartigimod or placebo, followed by a 5-week follow-up period. The primary endpoint was the change in MG-ADL total score from baseline to week 4 (day 29) in Part A. Part B is an open-label extension in which participants receive ongoing efgartigimod cycles with cycle initiation guided by clinical status from cycle 3 onward.

What the MG-ADL score measures

The MG-ADL (Myasthenia Gravis Activities of Daily Living) scale is an 8-item validated measure of the functional impact of myasthenia gravis symptoms on daily life. It evaluates: talking, chewing, swallowing, breathing, brushing teeth or combing hair, arising from a chair, double vision, and drooping eyelids. Each item is scored 0 to 3, with higher scores indicating greater impairment. A total score of 5 or higher at baseline indicates meaningful functional impairment. A reduction of 2 or more points is generally considered clinically meaningful.

Results

Outcome	Efgartigimod (VYVGART)	Placebo
Primary endpoint met	Yes (p=0.0068)	Reference
Mean change in MG-ADL at week 4	3.35-point improvement	Less than efgartigimod arm
Meaningful improvements across serotypes	Yes, all three: anti-MuSK, anti-LRP4, triple seronegative	—
QMG score improvement	Yes (Quantitative Myasthenia Gravis scale)	—
Sustained improvements through subsequent cycles	Yes, observed in Part B (open-label extension)	—
Safety profile	Consistent with established efgartigimod profile	—
New safety signals	None identified	—

Source: ADAPT SERON, NCT06298552. argenx press release, May 8, 2026. Presented at the 2026 MDA Clinical and Scientific Conference.

A 3.35-point improvement on the MG-ADL scale is clinically meaningful. To put that in concrete terms: it represents measurable improvement across the specific tasks, breathing, swallowing, speaking, seeing clearly, and performing basic physical movements, that gMG takes away from patients. In a population that had no indication-specific approved therapy before today, this result represents the first formal evidence of efficacy derived from a study built specifically around their diagnosis.

The improvement was observed across all three serotypes studied, which is the key finding from a regulatory standpoint. The FDA’s label expansion to cover all seronegative gMG is grounded in subgroup consistency: anti-MuSK, anti-LRP4, and triple seronegative patients all showed benefit in ADAPT SERON.

Safety: What Patients and Providers Need to Know

The safety profile in ADAPT SERON was consistent with efgartigimod’s established profile from prior trials in anti-AChR positive gMG and from its existing approvals for gMG and CIDP. No new safety signals were identified.

The most common adverse effects of VYVGART and VYVGART Hytrulo include:

Respiratory tract infection
Headache
Urinary tract infection
Injection site reactions (VYVGART Hytrulo only)

Important safety considerations from the prescribing information:

Infection risk: Because efgartigimod reduces total IgG levels (not just pathogenic antibodies), it also reduces some of the IgG antibodies that contribute to normal immune defense. Providers should delay treatment if a patient has an active infection. Patients should report any signs of infection promptly.
Allergic reactions: Serious hypersensitivity reactions can occur during or after infusion or injection. Patients should be monitored accordingly.
Infusion/injection-related reactions: Including elevated blood pressure, chills, and chest or back pain. These can occur during or shortly after administration.
Vaccinations: Live vaccines should be avoided during treatment. Discuss vaccination timing with your neurologist.
Pregnancy: Safety in pregnancy is not established. A pregnancy exposure registry is available at VYVGARTPregnancy.com or by calling 1-855-272-6524.

The full prescribing information for VYVGART and VYVGART Hytrulo is available through the FDA.

Two Administration Options: IV Infusion and Subcutaneous Injection

One practical note for patients navigating the treatment decision is that efgartigimod is now available in two administration formats, which differ in setting and convenience.

VYVGART (IV infusion): Administered intravenously in a clinical setting (infusion center or office). Each treatment cycle consists of 4 once-weekly infusions, approximately one hour per infusion.

VYVGART Hytrulo (subcutaneous injection): Administered as a subcutaneous injection, which can be self-administered at home with a prefilled syringe. This option uses Halozyme’s ENHANZE drug delivery technology to allow subcutaneous delivery of the same efgartigimod. For patients who prefer to avoid the infusion center setting, this represents a meaningful quality-of-life difference.

Both formulations are now approved for all adult gMG serotypes. The choice between them is made with a treating neurologist based on patient preference, access, and clinical circumstances.

The Equity Dimension: Why a Trial Built Around Seronegative Patients Matters

The structural problem that ADAPT SERON addressed is worth naming plainly. For decades, the way pivotal gMG trials were designed reflected and reinforced the treatment gap. Enrollment criteria typically required detectable anti-AChR antibodies for confirmation of diagnosis. This made sense from a scientific standpoint at the time: it reduced diagnostic uncertainty and created a more homogeneous trial population. But the effect was that seronegative patients, who make up roughly 20% of gMG cases and share the same debilitating disease, were systematically excluded from the evidence base that generated approved indications.

The consequence is not abstract. An FDA approval requires indication-specific evidence. Without trials that enrolled seronegative patients, no drug could carry an indication specific to their form of the disease. Without an indication, prescribing for this population operated in a gray zone, even when the same drugs were being used. For triple seronegative patients in particular, no approved drug had ever been studied or indicated specifically for them before today.

ADAPT SERON was built from the ground up to generate that evidence. The result is not just a label expansion for one drug. It is the first Phase 3 clinical evidence generated specifically for this population that has successfully supported FDA approval.

What Patients With gMG Should Know Right Now

If you have been diagnosed with gMG and your serotype is MuSK-positive, LRP4-positive, or triple seronegative

VYVGART and VYVGART Hytrulo are now FDA-approved for your specific serotype. This means they can be prescribed by your treating neurologist with an approved indication covering your diagnosis. The label expansion took effect May 8, 2026. Talk to your neurologist about whether this treatment is appropriate for your situation, including your current medication regimen, your disease activity, and whether the IV or subcutaneous administration option is a better fit for your circumstances.

If your antibody status is unknown or your diagnosis has not been fully characterized serologically

The expanded label means that clinicians can now prescribe efgartigimod based on a confirmed gMG diagnosis without requiring full serological characterization first. If your diagnosis has not included complete antibody testing (AChR, MuSK, and LRP4), discuss with your neurologist whether additional testing would be informative for your treatment planning.

Insurance coverage and access

Coverage decisions by insurers typically follow FDA approvals for rare disease treatments, but prior authorization requirements can create delays. The argenx patient support program, My VYVGART Path, provides access support, benefits verification, and financial assistance for eligible patients. More information is available at VYVGART.com.

For patients without insurance or with limited coverage, discuss options with your treatment center’s patient services team and review the argenx access support resources.

Finding a specialist

gMG is a rare disease and is ideally managed by or in consultation with a neurologist with expertise in neuromuscular disease. The Myasthenia Gravis Foundation of America (MGFA) maintains a physician directory and patient resources. The Muscular Dystrophy Association (MDA) also provides care resources, including MDA Care Centers with neuromuscular specialists. The National Organization for Rare Disorders (NORD) maintains a patient-facing overview of the disease and available resources.

Sources

argenx FDA approval press release: argenx Announces U.S. FDA Approval Expanding VYVGART and VYVGART Hytrulo for Use in All Adult Patients Living with gMG. GlobeNewswire. May 8, 2026.

MDA welcome statement: FDA Expands Approval of VYVGART and VYVGART Hytrulo to All Adults Living with Generalized Myasthenia Gravis. Muscular Dystrophy Association. May 8, 2026.

ADAPT SERON trial registration: NCT06298552. ClinicalTrials.gov.

NeurologyLive sBLA coverage: sBLA Acceptance Positions Efgartigimod as Potential First Therapy for Seronegative Myasthenia Gravis. NeurologyLive. February 2026.

Clinical Trial Vanguard analysis: FDA Expands Efgartigimod Approval to All Adult Generalized Myasthenia Gravis Patients. clinicaltrialvanguard.com. May 8, 2026.

FcRn biology: The neonatal Fc receptor (FcRn): a misnomer? PMC7211387.

MG-ADL scale reference: Validation of the MG-ADL scale. PMC6527389.

Neonatal myasthenia gravis: Neonatal Myasthenia Gravis. StatPearls. NCBI.

NINDS gMG overview: Myasthenia Gravis. National Institute of Neurological Disorders and Stroke.

MGFA patient resources: Myasthenia Gravis Foundation of America.

Patient resources: MGFA | MDA | NORD | VYVGART.com | VYVGARTPregnancy.com

Disclaimer: Health Evidence Digest provides general information about FDA approvals and health research for educational purposes only. Nothing on this site constitutes medical advice, diagnosis, or treatment. Decisions about myasthenia gravis treatment, including whether efgartigimod (VYVGART/VYVGART Hytrulo) is appropriate for your situation, should be made in consultation with a qualified neurologist or neuromuscular disease specialist who can evaluate your individual diagnosis, serotype, and treatment history.

May 11, 2026

Nexplanon Now Lasts 5 Years: What Women and Providers Need to Know About the FDA’s Extended Approval

What changed and when January 16, 2026: The FDA approved a supplemental NDA extending Nexplanon’s approved duration from 3 years to 5 years. February 23, 2026: New REMS (Risk Evaluation and Mitigation Strategy) program launched. Nexplanon is now only available through REMS-enrolled providers. August 23, 2026: Deadline by which all providers who insert or remove Nexplanon must complete REMS certification or lose ordering access. If you have a Nexplanon currently: it may now be left in place for up to 5 years from insertion, rather than 3. Discuss your specific timeline with your provider.

If you have a Nexplanon implant in your arm, there’s a good chance you’ve heard the three-year date coming up like a countdown. Get it out, replace it, or switch to something else. That schedule just changed.

On January 16, 2026, the FDA approved a supplemental new drug application from Organon extending Nexplanon’s approved duration of use from three years to five years. The approval is based on a clinical trial that followed 399 women through years four and five of continuous implant use and found zero pregnancies and no new safety findings. The same implant, the same arm, two additional years of coverage.

This post covers the clinical evidence behind the extension, what the new REMS program means for patients and providers, who can benefit from the extended duration and who should still remove at three years, and what to do if you have an implant right now.

What Nexplanon Is and How It Works

Nexplanon is a single-rod subdermal contraceptive implant, a small, flexible rod about 4 centimeters long and 2 millimeters wide, roughly the size of a matchstick. It is inserted just under the skin of the inner, non-dominant upper arm by a trained provider. It contains 68 mg of etonogestrel, a synthetic progestin, along with 15 mg of barium sulfate (which makes the implant visible on X-ray) and 0.1 mg of magnesium stearate.

Etonogestrel is released slowly and continuously from the implant into the bloodstream. It prevents pregnancy through three complementary mechanisms:

Suppression of ovulation: the primary mechanism. Etonogestrel inhibits the LH surge that triggers ovulation. No egg released means no pregnancy possible.
Thickening of cervical mucus: even if ovulation were to occur, thickened cervical mucus creates a barrier that sperm cannot penetrate effectively.
Modification of the endometrium: changes in the uterine lining create an additional unfavorable environment for implantation.

These three mechanisms together make Nexplanon one of the most effective contraceptive methods available. Its failure rate is less than 0.1% per year, lower than tubal ligation, vasectomy, IUDs, pills, patches, rings, and condoms. Unlike daily pills or monthly rings, it works without any ongoing action on the patient’s part: once inserted, it simply works.

It is also fully reversible. Fertility returns rapidly after removal, typically within days to weeks, not months. This makes it suitable for patients who want highly effective contraception now but may want to conceive in the future.

The Clinical Evidence Behind the 5-Year Extension

The FDA’s extension is based on data from a dedicated clinical trial designed specifically to evaluate contraceptive efficacy and safety during years four and five of use, the period for which no prior approval existed.

Study design

NCT04626596 was a multicenter, single-arm, open-label study conducted in the United States. It enrolled 399 women aged 18 to 35 who had been using a Nexplanon implant for exactly 36 months (within a two-week window). Participants continued using the same implant for an additional 24 months, with visits at months 6, 12, 18, and 24 of the extended period. The primary efficacy endpoint was the Pearl Index during years four and five.

The results

Measure	Result
Participants enrolled	399 women aged 18 to 35 (mean age 27)
Pregnancies during years 4 to 5	Zero
Pearl Index (years 4 to 5)	0.0 per 100 women-years (95% CI 0.00 to 0.69)
Mean BMI	29.4 kg/m² (range 17.2 to 64.3)
Participants with BMI 30 or above (obesity)	152 participants, 38.1%
Participants with BMI 40 or above (severe obesity)	40 participants, 10.0%
New safety findings in years 4 to 5	None
Safety profile vs. years 1 to 3	Consistent; no new or worsening signals
Most common adverse event (extended use)	Intermenstrual (irregular) bleeding

Source: NCT04626596. Organon press release January 16, 2026. FDA sNDA approval January 16, 2026.

The Pearl Index of 0.0, meaning zero pregnancies observed per 100 women-years of use, is the strongest possible contraceptive efficacy result. The upper bound of the 95% confidence interval (0.69) confirms that even accounting for statistical uncertainty, the maximum plausible pregnancy rate during years four and five remains well below 1 per 100 women-years. This is consistent with the established efficacy in years one through three.

The BMI data is important and clinically underappreciated Weight-based concerns about hormonal contraceptive efficacy are a common patient question. Higher body weight means more body fat, and progestin hormones can be distributed into fat tissue, potentially lowering circulating hormone levels. For some hormonal methods, particularly emergency contraception and some combined pills, this is a documented efficacy concern. For the etonogestrel implant, the clinical trial data has consistently shown maintained efficacy across a wide BMI range. The year 4 to 5 extension study enrolled participants with a mean BMI of 29.4, nearly at the obesity threshold, with a full 38% above BMI 30 and 10% above BMI 40. Zero pregnancies across this population is a meaningful data point for clinicians advising patients with obesity on contraceptive options. The updated label explicitly reflects this diversity.

Who Benefits From the Extended Duration and Who Should Still Remove at 3 Years

The 5-year approval is a maximum, not a mandate. Every patient’s situation is individual, and the right duration depends on goals, health status, and preferences.

Patients likely to benefit from extending to 5 years

Those who are satisfied with their current implant experience and have no plans to conceive in the next two years
Those who want to avoid an additional insertion/removal procedure, a minor but real burden for some patients
Those with irregular access to healthcare where scheduling a replacement at exactly 3 years is difficult
Those for whom cost is a factor: one fewer procedure and one fewer device every 5 years versus every 3

Patients who may prefer removal at or before 3 years

Those planning pregnancy in the next year or two
Those experiencing side effects (irregular bleeding, headache, mood changes, weight changes) that are troublesome and haven’t improved
Those who want to switch to a different contraceptive method
Those who have significant medical changes since insertion that affect contraceptive choice or introduce new contraindications

If You Have a Nexplanon Right Now: What This Means for You

This is the question most current implant users will want answered directly.

My implant is approaching or just past 3 years

The FDA approval means you now have the option to leave your existing implant in place for up to 5 years from the original insertion date, not 5 more years from now. Contact your provider to discuss whether extending is right for you. If you and your provider decide to extend, no procedure is needed; you simply continue as-is. If your implant has already been in place for more than 3 years and you were unaware of the extension, discuss with your provider promptly. The implant must be removed by the end of year 5.

My implant was recently inserted (within the last year or two)

When you approach the previously expected 3-year mark, you can now choose to stay with your current implant for an additional 2 years, as long as you remain a good candidate for continued use and have no contraindications at that point. No action needed now.

My implant was removed and replaced recently, or I’m planning removal

If you had your implant replaced at or before 3 years, you cannot retroactively extend the old implant. That device has been removed. Your new implant can now be used for up to 5 years from its insertion date. If you scheduled removal before learning about the extension and want to delay, contact your provider’s office to discuss.

The New REMS Program: What It Is and Why It Exists

Alongside the duration extension, the FDA required implementation of a new Risk Evaluation and Mitigation Strategy (REMS) for Nexplanon. A REMS is a safety program the FDA uses when a product has known or potential risks that require specific measures beyond standard labeling to manage safely. Nexplanon’s REMS exists specifically to address the risk of complications from improper insertion and removal.

Why improper insertion is a real concern

Nexplanon insertion is a minor procedure, but it is a procedure, and getting it wrong has consequences. An implant placed too deeply (intramuscular or beyond) can be difficult or impossible to remove without surgery. Migration, where the implant or a fragment moves from the insertion site, has been reported and sometimes requires more complex removal. Insertion near neurovascular structures can cause nerve damage. The REMS is designed to ensure that every provider who offers Nexplanon has the training to place it correctly, at the recommended depth and location, every time.

What the REMS requires for providers

Step	What’s Required
1. Register at nexplanonrems.com	Create an account at the REMS portal
2. Review the Healthcare Provider Guide	Read through the updated training materials
3. Review the Prescribing Information	Updated to reflect 5-year duration and BMI data
4. Complete Knowledge Assessment	7-question online quiz (~10 minutes total for steps 1 to 4)
5. Complete Enrollment Form	Submit to receive REMS certification
6. Complete in-person practical training	Required if not previously Organon-trained; includes competency checklist
7. Report insertion/removal events	Any complications must be reported using the IRRE form or by calling 1-833-NXP-REMS

Critical provider deadline: August 23, 2026 Providers who insert or remove Nexplanon must complete REMS certification by August 23, 2026. After this date, providers who have not enrolled will not be able to order or receive Nexplanon for insertion. The enrollment window opened February 23, 2026. For providers who completed Organon’s previous Clinical Training Program, the online REMS enrollment (steps 1 to 5 above) may be sufficient without additional in-person training, depending on whether training history is reflected in the portal. If the system indicates training is required despite prior completion, call 1-833-NXP-REMS (1-833-697-7367). There are no changes to the recommended insertion technique or location. The correct site remains 3 to 5 cm posterior to the sulcus between the biceps and triceps on the inner upper arm. Full guidance is available at nexplanonrems.com.

For patients: the REMS is a provider-side requirement. You do not need to do anything differently. It does mean that your provider must be REMS-certified to insert or remove your implant. If you are concerned about whether your current provider is enrolled, you can ask them directly or contact Organon’s REMS support line at 1-833-697-7367.

Safety, Side Effects, and Contraindications

Common side effects (from years 1 to 3 trials)

These were reported in at least 5% of clinical trial participants and remain the primary side effects to counsel patients about:

Headache (24.9%), the most common
Vaginitis (14.5%)
Weight increase (13.7%)
Acne (13.5%)
Breast pain (12.8%)
Abdominal pain (10.9%)
Pharyngitis/upper respiratory symptoms (10.5%)
Changes in menstrual bleeding patterns (the most common reason for discontinuation, at 11.1%)

Menstrual pattern changes deserve specific mention because they are common and often unexpected. Nexplanon can cause irregular spotting or light bleeding, more frequent bleeding, less frequent bleeding, or complete absence of periods, and the pattern that develops in the first three months is broadly predictive of what to expect going forward. This is not a sign of pregnancy or a problem; it is a normal pharmacological effect of progestin on the endometrium. For patients who find their bleeding pattern unacceptable, removal and method change remains an option at any time.

Contraindications: who should not use Nexplanon

Per the updated prescribing information, Nexplanon is contraindicated in patients with:

Known or suspected pregnancy
Current or past history of thrombosis or thromboembolic disorders
Liver tumors (benign or malignant) or active liver disease
Undiagnosed abnormal uterine bleeding
Known or suspected breast cancer, personal history of breast cancer, or other progestin-sensitive cancer
Allergy to any component of Nexplanon

Drug interactions to know

Certain medications that induce the CYP3A4 enzyme, including rifampin, some anti-seizure medications (carbamazepine, phenytoin, phenobarbital), and St. John’s Wort, can accelerate etonogestrel metabolism and potentially reduce implant efficacy. Patients starting these medications should discuss contraceptive options with their provider. The implant does not interact with most common medications.

Cost and Insurance Coverage

Under the Affordable Care Act, most private insurers are required to cover FDA-approved contraceptive methods without cost-sharing, meaning $0 out-of-pocket for the patient, including the device and the insertion procedure. This applies to Nexplanon. However, coverage details vary by plan, and some plans have grandfathered exemptions or denominational exemptions. It is always worth verifying with your specific insurer.

For uninsured or underinsured patients, the 5-year duration represents meaningful cost savings, one fewer device and insertion procedure per 10 years of use compared to the 3-year schedule. Title X family planning clinics provide Nexplanon on a sliding-scale fee basis. Organon’s patient support program can assist with coverage navigation; contact information is available at organon.com.

This extension is part of a broader pattern of evidence-based updates improving access to women’s reproductive healthcare in 2026. For related coverage, see our post on new 2026 cervical cancer self-collection screening guidelines and our overview of GLP-1 medications and PCOS fertility research.

Do you have questions about your implant or your timeline?

The FDA’s 5-year extension is a straightforward evidence-based update: the implant keeps working, the safety profile stays consistent, and women with BMI across a wide range continue to be protected. For women with a current implant approaching the 3-year mark, the conversation with your provider is now richer; you have a real choice rather than an automatic expiration date. For providers: the REMS enrollment deadline of August 23, 2026 is actionable now. The enrollment process at nexplanonrems.com takes approximately 10 minutes for those who have completed prior training. Bedsider’s provider resource page and the Reproductive Health Access Project have step-by-step REMS guides for clinical teams.

Sources

Organon press release: Organon Announces FDA Approval of sNDA Extending Duration of Use of NEXPLANON (etonogestrel implant) 68 mg Radiopaque. January 16, 2026.

FDA updated prescribing information: NEXPLANON Prescribing Information (2026). accessdata.fda.gov.

Clinical trial registration: NCT04626596: Study to Assess Contraceptive Efficacy and Safety of ENG Implant Beyond 3 Years of Use. ClinicalTrials.gov.

Contemporary OB/GYN: FDA approves 5-year use for etonogestrel implant 68 mg contraceptive. contemporaryobgyn.net. January/March 2026.

ReproHH (UCSF): FDA Approves Updated Nexplanon Label and Launches New REMS: What to Know. reprohh.ucsf.edu. February 2026.

Reproductive Health Access Project: Contraceptive Pearl: New FDA REMS Requirement on Nexplanon. reproductiveaccess.org. March 2026.

Bedsider for providers: Nexplanon REMS Requirements: What Providers Need to Know. providers.bedsider.org. March 2026.

Organon Pro (REMS FAQs): FAQs: NEXPLANON for HCPs. organonpro.com.

REMS enrollment: nexplanonrems.com. REMS support: 1-833-NXP-REMS (1-833-697-7367)

ACOG LARC resource: Long-Acting Reversible Contraception: Intrauterine Device and Implant. ACOG.

Disclaimer: Health Evidence Digest provides general information about FDA approvals and health research for educational purposes. This content is not a substitute for professional medical advice. Decisions about contraceptive methods, including whether to extend Nexplanon use to 5 years, should be made in consultation with a qualified healthcare provider who can account for your individual health history and circumstances.

May 3, 2026

A Historic First: FDA Approves Immunotherapy for Platinum-Resistant Ovarian Cancer — What the KEYNOTE-B96 Data Tells Us

📌 The essentials On February 10, 2026, the FDA approved pembrolizumab (Keytruda, Merck) in combination with paclitaxel, with or without bevacizumab, for adult patients with platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal carcinoma whose tumors express PD-L1 (combined positive score, or CPS, of at least 1). The approval covers patients who have received one or two prior lines of systemic therapy. This is the first FDA-approved immunotherapy for ovarian cancer in history. The clinical basis: KEYNOTE-B96/ENGOT-ov65 (NCT05116189), a randomized, double-blind, placebo-controlled Phase 3 trial in 643 patients, showed median overall survival of 18.2 months versus 14.0 months with placebo (HR 0.76; p=0.0053) in the PD-L1 CPS of 1 or higher population. The first statistically significant OS benefit ever demonstrated by an immune checkpoint inhibitor in ovarian cancer. A companion diagnostic requirement: Tumor testing with the PD-L1 IHC 22C3 pharmDx assay confirming CPS of 1 or higher is required before treatment. This is a requirement, not a recommendation.

Ovarian cancer has resisted immunotherapy for decades. Every major trial of immune checkpoint inhibitors in this disease came back negative or borderline, results that didn’t survive longer follow-up. The field watched other gynecologic cancers, particularly cervical and endometrial, respond to PD-1 blockade while ovarian cancer remained stubbornly outside that story.

That changed on February 10, 2026.

The FDA approved pembrolizumab (Keytruda, Merck) in combination with paclitaxel, with or without bevacizumab, for adult patients with platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal carcinoma whose tumors express PD-L1 (CPS of at least 1). The approval covers patients who have received one or two prior lines of systemic therapy.

It is the first FDA-approved immunotherapy for ovarian cancer in history.

This post covers what platinum resistance means and why it matters, what KEYNOTE-B96 showed across its primary and key secondary endpoints, how to read the survival data carefully, what the companion diagnostic approval means in practice, and what questions are still open.

Platinum Resistance: Why This Setting Is So Hard to Treat

Most women with advanced ovarian cancer respond well to their first-line treatment, typically surgery followed by platinum-based chemotherapy, often combined with a taxane and increasingly with PARP inhibitors as maintenance. Response rates in the frontline setting can exceed 70 to 80%.

The problem is recurrence. About 70 to 80% of patients with advanced ovarian cancer relapse after initial treatment. When recurrence happens, the most important prognostic factor is how quickly it occurs after the last platinum therapy. Patients whose disease progresses more than six months after platinum are classified as platinum-sensitive and can be retreated with platinum. Patients whose disease progresses within six months are classified as platinum-resistant.

Platinum resistance is a watershed moment in the treatment arc. Non-platinum options, including weekly paclitaxel, pegylated liposomal doxorubicin, gemcitabine, and bevacizumab, produce response rates in the 10 to 20% range and median progression-free survival measured in months. Median overall survival in platinum-resistant ovarian cancer has historically ranged from roughly 12 to 16 months. These patients carry significant unmet need, and the disease is hard to control with anything currently available.

That is the context in which the KEYNOTE-B96 results need to be understood.

The KEYNOTE-B96 Trial: Design and Patient Population

KEYNOTE-B96 (also known as ENGOT-ov65, NCT05116189) was a multicenter, randomized, double-blind, placebo-controlled Phase 3 trial enrolling 643 patients with histologically confirmed epithelial ovarian, fallopian tube, or primary peritoneal carcinoma. Eligibility required:

Platinum-resistant disease, defined as radiographic progression within six months of the last platinum-based regimen
One or two prior lines of systemic therapy for ovarian carcinoma
At least one prior platinum-based chemotherapy regimen
Measurable disease by RECIST v1.1

Patients with primary platinum-refractory disease, meaning progression during or immediately after first-line platinum, were excluded.

Patients were randomized 1:1 to pembrolizumab plus weekly paclitaxel (80 mg/m² on days 1, 8, and 15 of each 3-week cycle), with or without bevacizumab (10 mg/kg every two weeks), or placebo plus the same backbone. Bevacizumab use was at investigator’s discretion and was a stratification factor. Stratification also included geographic region and PD-L1 expression by CPS.

The primary endpoint was investigator-assessed progression-free survival (PFS) by RECIST v1.1, evaluated first in the PD-L1 CPS of 1 or higher population, then in the ITT population. Overall survival was a key secondary endpoint.

What is PD-L1 CPS and why does it determine eligibility? PD-L1 Combined Positive Score (CPS) measures PD-L1 protein expression across tumor cells, tumor-associated lymphocytes, and macrophages. A CPS of 1 or higher means at least 1 PD-L1-staining cell per 100 tumor cells was detected. This is a relatively low threshold: in KEYNOTE-B96, approximately 466 of 643 patients (roughly 72%) had CPS of 1 or higher. The FDA approval is restricted to CPS of 1 or higher patients, where both PFS and OS benefits were demonstrated. The ITT population also showed significant PFS improvement, but the OS benefit was most clearly established in the CPS of 1 or higher group. This matters in practice: before receiving this regimen, a patient’s tumor must be tested with the FDA-approved companion diagnostic, the PD-L1 IHC 22C3 pharmDx assay, and return a CPS of 1 or higher result. This is a requirement, not a recommendation.

The Results: Progression-Free Survival and Overall Survival

The trial conducted two pre-specified interim analyses. The second (IA2), with a data cutoff of May 5, 2025, was presented at ESMO Congress 2025 in Berlin in October 2025 and formed the basis for the February 2026 FDA approval. Final OS data were subsequently published in The Lancet in April 2026.

Progression-Free Survival

In the PD-L1 CPS of 1 or higher population (n=466), median PFS was 8.3 months with pembrolizumab versus 7.2 months with placebo, with a hazard ratio of 0.72 (95% CI 0.58 to 0.89; p=0.0014). The 12-month PFS rate was 35.2% for pembrolizumab versus 22.6% for placebo.

In the ITT population (all 643 patients), median PFS was 8.3 versus 6.4 months (HR 0.70; 95% CI 0.58 to 0.84; p less than 0.0001), with 12-month PFS rates of 33.1% versus 21.3%.

These are statistically significant and clinically meaningful improvements in a setting where six months of progression-free survival is often considered a reasonable benchmark.

Overall Survival

Among the 466 PD-L1 CPS of 1 or higher patients, median OS was 18.2 months in the pembrolizumab arm versus 14.0 months with placebo, a hazard ratio of 0.76 (95% CI 0.61 to 0.94; p=0.0053). The 12-month OS rate was 69.1% versus 59.3%. The 18-month OS rate was 51.5% versus 38.9%.

A four-month improvement in median OS. The first statistically significant overall survival benefit ever shown by an immune checkpoint inhibitor in ovarian cancer.

Endpoint	Pembrolizumab plus chemo	Placebo plus chemo	HR (95% CI)	P-value
Median PFS (CPS of 1 or higher)	8.3 months	7.2 months	0.72 (0.58 to 0.89)	0.0014
Median PFS (ITT)	8.3 months	6.4 months	0.70 (0.58 to 0.84)	less than 0.0001
Median OS (CPS of 1 or higher)	18.2 months	14.0 months	0.76 (0.61 to 0.94)	0.0053
12-month OS (CPS of 1 or higher)	69.1%	59.3%	—	—
18-month OS (CPS of 1 or higher)	51.5%	38.9%	—	—

Source: KEYNOTE-B96/ENGOT-ov65 Phase 3 trial, IA2 (data cutoff May 5, 2025). Final OS data: The Lancet, April 2026. FDA approval: February 10, 2026.

How to Read These Numbers Carefully

A four-month improvement in median OS is real and clinically meaningful in this setting, particularly given the historical absence of any survival benefit from immunotherapy in ovarian cancer. But it is worth understanding what the numbers do and don’t tell us.

The hazard ratio of 0.76 means that at any given point during the trial, patients in the pembrolizumab arm had a 24% lower risk of death than those in the placebo arm. This is not a cure. It is a reduction in the rate of events that translates into prolonged survival for a meaningful portion of patients. The 18-month OS rate shifting from 38.9% to 51.5% is the clearest way to see this: at 18 months, roughly one in eight additional patients were alive in the pembrolizumab arm compared to the placebo arm.

The approval is restricted to CPS of 1 or higher. About 72% of patients in KEYNOTE-B96 met this threshold, so most platinum-resistant ovarian cancer patients would be eligible for testing, but not all will test positive.

Median survival describes the midpoint of the distribution, not individual patient outcomes. Some patients in the pembrolizumab arm had substantially longer survival than 18 months. The final OS data from The Lancet publication provides a clearer view of the tail of the survival curve, which will help clarify whether there is a subset of patients with especially durable benefit, the pattern that checkpoint inhibitors sometimes produce in other tumors.

The Companion Diagnostic: What the PD-L1 Test Means in Practice

The FDA simultaneously approved the PD-L1 IHC 22C3 pharmDx assay (Agilent Technologies) as a companion diagnostic for identifying eligible patients. Tumor PD-L1 testing confirming CPS of 1 or higher is required before treatment, not optional.

The 22C3 pharmDx assay is the same companion diagnostic used in pembrolizumab approvals across multiple other tumor types, including cervical, endometrial, esophageal, and gastric cancers. At most academic medical centers and major oncology practices, this test is already part of the standard pathology workflow. At community oncology centers or in lower-resource settings, access to and turnaround time on the assay is a practical consideration worth discussing with the treating team.

Tumor tissue for PD-L1 testing can come from the original diagnosis or a recurrence biopsy. Given that PD-L1 expression can change with disease progression, some oncologists may prefer more recently collected tissue, though the label does not mandate this.

What about bevacizumab? The approved regimen is pembrolizumab plus paclitaxel, with or without bevacizumab. Bevacizumab (Avastin) is an anti-VEGF antibody with established activity in ovarian cancer, including in the platinum-resistant setting. Its use in KEYNOTE-B96 was at investigator discretion and was a stratification factor. Patients with contraindications to anti-VEGF therapy, such as certain cardiovascular risk factors, recent major surgery, a history of GI perforation, or significant proteinuria, can receive pembrolizumab plus paclitaxel without bevacizumab. Review the full Keytruda prescribing information for complete contraindication guidance.

Why Previous Immunotherapy Trials in Ovarian Cancer Failed, and Why This One Didn’t

The history of checkpoint inhibitor trials in ovarian cancer before KEYNOTE-B96 is largely a story of negative results. Earlier Phase 3 trials, including atezolizumab plus chemotherapy in frontline and maintenance settings, did not demonstrate meaningful survival improvements. Single-agent anti-PD-1 trials showed modest response rates of 10 to 15% in unselected ovarian cancer patients.

Several factors likely contributed. Ovarian cancer has a relatively immunosuppressive tumor microenvironment, with high regulatory T cell infiltration, immunosuppressive cytokines, and ascites fluid that dampens immune activity. Tumor mutational burden is generally lower than in cancers like melanoma or lung cancer that respond robustly to checkpoint inhibitors. And earlier trials often did not select for PD-L1 expression.

KEYNOTE-B96 made design choices that may have improved its chances. The combination with weekly paclitaxel, a metronomic dosing schedule thought to have immunomodulatory properties alongside its cytotoxic effects, may have made the tumor microenvironment more permissive to immune infiltration. The CPS of 1 or higher selection enriched for a more immunologically accessible population. These are mechanistic hypotheses with biological plausibility, not proven causal explanations, but they provide a rational basis for why this combination in this specific population succeeded where broader efforts did not.

Safety: What Patients and Clinicians Need to Know

The safety profile of the pembrolizumab combination in KEYNOTE-B96 was consistent with prior pembrolizumab trials. No new safety signals were identified.

Pembrolizumab carries immune-mediated adverse reactions as a class, the consequence of broadly activating the immune system. These can affect virtually any organ system.

Key immune-mediated risks:

Pneumonitis: inflammation of the lungs; monitor for new or worsening respiratory symptoms
Colitis: diarrhea and abdominal pain; may require corticosteroids or discontinuation
Hepatitis: elevated liver enzymes; regular LFT monitoring during treatment
Endocrinopathies: thyroid dysfunction, adrenal insufficiency, type 1 diabetes mellitus, hypophysitis
Nephritis: elevated creatinine; monitor renal function
Dermatologic reactions: rash, rare severe skin reactions including Stevens-Johnson syndrome

Most immune-mediated adverse reactions are manageable with corticosteroids if caught early. The prescribing information outlines detailed management algorithms, including when to hold versus permanently discontinue pembrolizumab.

Other warnings:

Infusion-related reactions: fever, chills, hypotension, and bronchospasm are possible. Standard premedication and monitoring protocols apply.

Embryo-fetal toxicity: pembrolizumab can cause fetal harm. Women of reproductive potential should use effective contraception during treatment and for at least four months after the final dose.

Dosing:

The approved pembrolizumab dose is 200 mg IV every three weeks or 400 mg IV every six weeks, until disease progression, unacceptable toxicity, or up to 24 months of treatment. Pembrolizumab is administered before paclitaxel and bevacizumab when given on the same day.

Keytruda Qlex, a subcutaneous formulation combining pembrolizumab with berahyaluronidase alfa-pmph, was also approved. The subcutaneous dose is 395 mg/4,800 units every three weeks or 790 mg/9,600 units every six weeks, and can be administered in approximately five to ten minutes rather than the 30-minute IV infusion. For patients receiving multiple cycles over months of treatment, this is a real reduction in clinic time.

Open Questions and the Road Ahead

The KEYNOTE-B96 approval opens a new chapter in ovarian cancer treatment, but several clinical questions will shape how the approval is used in practice.

How durable is the benefit?

The final OS data in The Lancet provides longer follow-up than the interim analysis. The field will be watching for a favorable tail on the survival curve, the pattern suggesting a subset of patients achieve especially prolonged disease control, which checkpoint inhibitors produce in some tumor types.

Does PD-L1 CPS fully capture who responds?

CPS of 1 or higher is a broad threshold. Within the PD-L1-positive population there is likely meaningful heterogeneity in response. Future work will examine whether higher CPS thresholds, tumor mutational burden, microsatellite instability status, or tumor-infiltrating lymphocyte density can further refine patient selection.

What about earlier lines of therapy?

The positive KEYNOTE-B96 result will prompt investigators to ask whether pembrolizumab-containing regimens have a role in the frontline or maintenance setting in ovarian cancer. Several trials are already exploring this. The data in those settings will need to be evaluated on their own terms.

Sequencing after progression on this regimen:

The approval covers patients after one or two prior regimens. What comes next for patients who progress on pembrolizumab plus chemotherapy? The treatment landscape at third or later lines remains difficult, and ongoing trials will need to address sequencing questions. ClinicalTrials.gov is the primary resource for identifying open studies.

Project Orbis: A Global Review Pathway This approval was reviewed under Project Orbis, an FDA Oncology Center of Excellence initiative enabling concurrent submission and review across multiple international regulatory agencies. For KEYNOTE-B96, FDA collaborated with Australia’s Therapeutic Goods Administration, Health Canada, and Switzerland’s Swissmedic. Project Orbis doesn’t mean all countries approve simultaneously; each agency makes its own decision. But it creates a framework for data sharing that can accelerate global access. The designation signals that review is underway or completed in partner countries.

What This Means for Patients With Platinum-Resistant Ovarian Cancer

For patients who have progressed after one or two lines of therapy and are now facing platinum-resistant disease, the conversation with their oncologist includes a genuinely new option for the first time. Pembrolizumab plus paclitaxel, with or without bevacizumab, is not a marginal refinement. It is the first regimen to improve overall survival in this population in a Phase 3 trial.

The first step is PD-L1 testing. Patients whose disease has not been recently biopsied may want to discuss with their oncologist whether fresh tissue for biomarker testing is feasible and clinically appropriate at the time of progression.

For related coverage of how immunotherapy and ADC approvals are expanding across gynecologic and breast cancers in 2026, see our posts on Dato-DXd in triple-negative breast cancer, vepdegestrant and the first PROTAC approval in oncology, and what the FDA’s contrasting decisions on camizestrant and vepdegestrant reveal about the future of ESR1-guided treatment.

Patient advocacy organizations with resources for ovarian cancer include the Ovarian Cancer Research Alliance, the National Ovarian Cancer Coalition, and the Foundation for Women’s Cancer. All three maintain clinical trial databases and physician directories. Patients interested in trials evaluating pembrolizumab in earlier-line ovarian cancer settings can search for open studies at ClinicalTrials.gov.

Sources

FDA approval: FDA Approves Pembrolizumab with Paclitaxel for Platinum-Resistant Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Carcinoma. February 10, 2026. FDA.gov.

KEYNOTE-B96 trial registration: NCT05116189. ClinicalTrials.gov.

ESMO 2025 abstract: Colombo N et al. Pembrolizumab vs Placebo Plus Weekly Paclitaxel plus/minus Bevacizumab in Platinum-Resistant Recurrent Ovarian Cancer. LBA3. ESMO Congress 2025, Berlin, October 2025.

Final OS publication: KEYNOTE-B96/ENGOT-ov65 final overall survival analysis. The Lancet. April 2026.

Merck press release: Merck Announces Phase 3 KEYNOTE-B96 Trial Met Primary Endpoint of Progression-Free Survival. May 2025. merck.com.

OncLive approval coverage: KEYNOTE-B96 Approval Reinforces the Shift Toward Biomarker-Driven Treatment in Recurrent PROC. OncLive. March 2026.

Clinical review: The role of chemo-immunotherapy in platinum-resistant ovarian cancer in light of the KEYNOTE-B96 trial. PubMed Central.

Keytruda prescribing information: Keytruda (pembrolizumab) and Keytruda Qlex Prescribing Information. Merck. 2026.

Keytruda Qlex FDA approval: FDA approves pembrolizumab and berahyaluronidase alfa-pmph (Keytruda Qlex) for multiple indications.

Companion diagnostic: PD-L1 IHC 22C3 pharmDx. FDA list of cleared or approved companion diagnostics.

Project Orbis: Project Orbis. FDA Oncology Center of Excellence.

Patient resources: Ovarian Cancer Research Alliance | National Ovarian Cancer Coalition | Foundation for Women’s Cancer | ClinicalTrials.gov

Disclaimer: Health Evidence Digest provides general health and regulatory information for educational purposes. This content is not a substitute for professional medical advice, diagnosis, or treatment. Treatment decisions for ovarian cancer should be made in consultation with a board-certified gynecologic oncologist experienced in managing platinum-resistant disease.

May 1, 2026

IZERVAY Can Now Be Used Beyond 12 Months. The Two-Year GATHER2 Data That Earned That Label Change and What It Means for Patients with Geographic Atrophy.

📌 The essentials On February 13, 2025, the FDA approved an expanded label for IZERVAY (avacincaptad pegol intravitreal solution, Astellas Pharma), removing the 12-month treatment duration limit that was part of the original August 2023 approval. The drug is now approved without restriction on duration of treatment. The clinical basis: Two-year data from the GATHER2 Phase 3 trial (NCT04435366), published in Ophthalmology in December 2025, showing that the treatment benefit of IZERVAY more than doubled between year one and year two of continuous treatment. The year-two data also showed that every-other-month (EOM) dosing maintained efficacy comparable to monthly dosing, offering a meaningful reduction in treatment burden for patients who tolerate the drug. Who this matters for: Patients currently on IZERVAY approaching or past the previous 12-month ceiling, and patients with geographic atrophy (GA) secondary to AMD who have not yet started treatment and are weighing their options.

Geographic atrophy is the advanced form of dry age-related macular degeneration, and until 2023, it had no approved treatments. Patients watched their central vision deteriorate with nothing to offer but AREDS2 vitamins to slow progression to the advanced stage. That changed when the FDA approved two complement inhibitors in the same year: pegcetacoplan (Syfovre, Apellis) in February 2023 and avacincaptad pegol (IZERVAY, Astellas) in August 2023. For the first time, retinal specialists had tools, modest ones but real ones, to slow the growth of GA lesions.

The original IZERVAY approval carried a limitation: the label authorized treatment for up to 12 months. That ceiling reflected the data available at the time of initial approval. But the GATHER2 Phase 3 trial continued beyond that point, and its two-year results are now in.

On February 13, 2025, the FDA approved an expanded label for IZERVAY, removing the 12-month dosing limit. The drug is now approved without a restriction on duration of treatment. The updated label is based on two-year data from GATHER2 showing that the benefit of IZERVAY continued to grow over time, more than doubling between year one and year two.

This post covers what geographic atrophy is and why treatment is difficult, how IZERVAY works, what the full GATHER2 data shows through two years, what the label change means in practice, and how IZERVAY sits in the context of the two available GA treatments.

Geographic Atrophy: The Disease Behind the Drug

Age-related macular degeneration (AMD) is the leading cause of central vision loss in adults over 50 in the developed world, affecting the macula, the small, high-acuity central area of the retina responsible for reading, recognizing faces, and driving. AMD progresses along a spectrum from early (drusen deposits, pigment changes) through intermediate to advanced forms.

Advanced AMD has two forms. Neovascular AMD (wet AMD) involves abnormal blood vessel growth beneath the retina, causing rapid vision loss that is treatable with anti-VEGF injections. Geographic atrophy (GA), the dry advanced form, involves progressive loss of retinal pigment epithelial (RPE) cells, photoreceptors, and the underlying choriocapillaris. The name comes from the appearance of the lesions on imaging: well-demarcated, map-like areas of atrophy that expand over time. GA progresses slowly but relentlessly, with no reversal of lost retinal tissue.

An estimated one million Americans have geographic atrophy. As GA expands toward the central fovea, it causes an increasingly large, permanent blind spot in central vision. The impact on reading, driving, and face recognition is severe. Because the process is slow and does not cause the sudden dramatic vision loss seen in wet AMD, patients sometimes do not realize the extent of their deterioration until it is substantial.

Why GA is hard to treat and why lesion growth is the primary endpoint The complement system plays a central role in GA pathogenesis. Genome-wide association studies have identified complement factor H (CFH) variants as the strongest genetic risk factor for advanced AMD. Complement dysregulation causes chronic inflammation, drusen deposition, and formation of the membrane attack complex (MAC), which destroys RPE cells and photoreceptors. Because no treatment can restore dead retinal cells, approved therapies for GA are designed to slow the rate of lesion expansion, measured by area of GA on fundus autofluorescence imaging, rather than improve vision directly. Neither of the two approved GA drugs has demonstrated statistically significant improvement in best-corrected visual acuity (BCVA) in their pivotal trials. This is not a failure of the drugs; it reflects the biology of a slowly progressive disease where even a meaningful structural benefit may not translate to measurable visual gains over 12 to 24 months. The FDA accepted lesion growth rate as an acceptable primary endpoint for approval. The European Medicines Agency took a different position, declining to approve Syfovre on the grounds that lesion slowing was not sufficient evidence of clinically meaningful patient benefit. That regulatory distinction is worth understanding when comparing how this drug class is viewed globally.

How IZERVAY Works: C5 Inhibition and the Complement Cascade

IZERVAY (avacincaptad pegol) is a pegylated RNA aptamer, a chemically modified oligonucleotide rather than a monoclonal antibody, that specifically inhibits complement protein C5. Understanding why C5 is the target and what an RNA aptamer is helps make sense of both the mechanism and the safety profile.

The complement cascade and C5’s role

The complement system is a network of proteins that form a critical arm of innate immunity. When activated, the cascade converges on two central reactions: cleavage of complement component C3 into C3a and C3b, and then cleavage of C5 into C5a and C5b. C5a is a potent pro-inflammatory mediator. C5b initiates assembly of the membrane attack complex (MAC), a protein complex that punches holes in cell membranes and destroys them. In GA, chronic overactivation of the complement pathway leads to persistent MAC formation and progressive destruction of RPE cells and photoreceptors.

IZERVAY blocks C5 cleavage, preventing formation of both C5a and C5b and therefore preventing downstream MAC assembly. Because C5 sits near the terminal end of the cascade, inhibiting it preserves upstream complement activity, including C3 function and opsonization, while specifically blocking the terminal destructive pathway implicated in GA.

What makes avacincaptad pegol an RNA aptamer

Unlike the monoclonal antibodies used in wet AMD (ranibizumab, bevacizumab, aflibercept), avacincaptad pegol is an RNA aptamer: a short, precisely folded strand of chemically modified RNA that binds its target protein, complement C5, with high specificity. The pegylation (attachment of polyethylene glycol chains) extends its half-life in the eye and improves stability. It is delivered as a 100 μL intravitreal injection directly into the vitreous humor of the eye.

C5 vs. C3: Two targets, two drugs IZERVAY (avacincaptad pegol) targets C5, near the terminal end of the complement cascade. Syfovre (pegcetacoplan) targets C3, which sits upstream at the convergence of all three complement activation pathways (classical, alternative, and lectin). The theoretical advantage of C5 inhibition is that it preserves upstream C3 activity, including opsonization of pathogens and apoptotic cells, while blocking the terminal destructive MAC. The theoretical advantage of C3 inhibition is broader suppression of the cascade. Neither advantage has been definitively demonstrated to be clinically superior in head-to-head data. What is clear is that the two drugs have meaningfully different safety profiles, particularly regarding intraocular inflammation. Rare but serious cases of retinal vasculitis have been reported with pegcetacoplan in post-marketing surveillance. That signal has not been observed with avacincaptad pegol in clinical trials.

The GATHER Trial Program: From Phase 2/3 to the Two-Year Label Change

The evidence base for IZERVAY rests on two Phase 3 trials: GATHER1 and GATHER2. Both evaluated monthly 2 mg intravitreal injections of avacincaptad pegol versus sham in patients with non-center-point-involving GA secondary to AMD. The primary endpoint in both was GA lesion growth rate measured by fundus autofluorescence.

GATHER1: Initial evidence and original approval

GATHER1 (NCT02686658) enrolled 286 patients across 12 months of treatment. The trial evaluated doses of 2 mg and 4 mg versus sham. The 2 mg dose reduced GA lesion growth rate by 27.4% (p=0.0072) and the 4 mg dose by 27.8% (p=0.0051) compared with corresponding sham groups. The 2 mg dose was selected for further development based on its favorable benefit-risk profile. These data, combined with GATHER2, formed the basis of the original August 2023 FDA approval.

GATHER2: The Phase 3 confirmatory trial through two years

GATHER2 (NCT04435366) was a randomized, double-masked, sham-controlled, multicenter Phase 3 trial enrolling 448 patients. For the first 12 months, patients received monthly IZERVAY 2 mg or sham. At month 12, patients originally assigned to IZERVAY were re-randomized to continue monthly (EM, n=96) or switch to every-other-month dosing (EOM, n=93). Sham patients continued on sham through year two (n=203).

Timepoint	IZERVAY vs. Sham: GA growth rate reduction	Statistical significance
Year 1 (Month 12)	14% reduction in monthly group vs. sham	p less than 0.01 (primary endpoint met)
Year 2 (Month 24), every-month dosing (EM)	Treatment benefit continued; total benefit more than doubled vs. year 1	Maintained vs. sham
Year 2 (Month 24), every-other-month (EOM)	Treatment benefit maintained at comparable level to EM	Maintained vs. sham
Onset of benefit	Observed as early as 6 months	Statistically significant from month 6 onward

Source: Khanani AM et al. Ophthalmology. Published online December 15, 2025. doi:10.1016/S0161-6420(25)00790-0

The two-year findings carry a clinically important message: the benefit of IZERVAY did not plateau or diminish with continued treatment. It grew. The reduction in GA growth rate more than doubled between year one and year two, suggesting that the treatment effect compounds over time as the drug continues to suppress terminal complement activation and MAC formation. This is consistent with the biology: continuous inhibition of the destructive pathway progressively spares more retinal tissue relative to an untreated eye.

The every-other-month data in year two is also practically significant. Reducing injection frequency from monthly to bimonthly without loss of efficacy substantially reduces the treatment burden for patients who are tolerating therapy. Fewer clinic visits and injections per year is a meaningful quality-of-life consideration for an older patient population managing multiple chronic conditions.

Safety Through Two Years: What the GATHER2 Data Shows

The safety profile of IZERVAY over two years in GATHER2 was consistent with year-one observations, with no new or significant signals. For patients and prescribers making long-term treatment decisions, the two-year safety picture matters as much as the efficacy data.

Adverse event	IZERVAY (2-yr data)	Clinical note
Endophthalmitis (eye infection)	1 case (culture-positive, non-serious)	Rare; inherent risk of any intravitreal injection
Intraocular inflammation (serious)	0 cases	No serious IOI; no cases of retinal vasculitis
Ischemic optic neuropathy	0 cases	Safety signal seen with Syfovre; absent here
Choroidal neovascularization (CNV)/wet AMD conversion	IZERVAY: 11.6% vs. Sham: 9.0%	Small numerical increase; class effect for complement inhibitors
Conjunctival hemorrhage (most common AE)	Common	Typical injection-site reaction; self-limiting
Increased intraocular pressure	Common	Transient; monitored post-injection
Blurred vision	Common	Typically transient

The absence of serious intraocular inflammation, retinal vasculitis, and ischemic optic neuropathy over two years is a notable feature of the IZERVAY safety profile. These events have been reported in post-marketing surveillance with pegcetacoplan (Syfovre), and their absence in GATHER2 is meaningful context for the prescribing decision.

The small numerical increase in choroidal neovascularization (wet AMD conversion) with IZERVAY, 11.6% versus 9% in the sham group, is a known class effect of complement inhibition shared to some degree by both approved GA drugs. Complement pathway suppression may alter the balance of angiogenic regulation in the retina. Patients receiving IZERVAY should be monitored for signs of wet AMD conversion: visual distortions, straight lines appearing bent, or new deterioration in central vision.

Key contraindications and precautions for IZERVAY Do not use IZERVAY in patients with: Active ocular or periocular infection; Active intraocular inflammation; History of or active choroidal neovascularization (wet AMD). Monitor for and counsel patients to report: Redness, pain, increased discomfort, worsening redness, or decreased/blurred vision after injection, which may be signs of endophthalmitis or retinal detachment; Visual distortions or new central vision changes, which may be signs of wet AMD conversion; Flashes of light or increased floaters, which may be signs of possible retinal complications. Patients should not drive or use machinery until vision has recovered after each injection. Full prescribing information is available at accessdata.fda.gov.

What Removing the 12-Month Cap Means in Practice

The original IZERVAY approval in August 2023 included a duration limitation: the label authorized use for up to 12 months. This ceiling was not arbitrary. It reflected the controlled trial data available at the time of the initial BLA, which covered only year-one efficacy and safety from GATHER2.

Following a regulatory path that included a supplemental NDA submission, an initial Complete Response Letter from the FDA in November 2024, a rapid resubmission in December 2024, and FDA approval on February 13, 2025, the label no longer carries that limitation.

Before (original label)	After (updated label, Feb 2025)
Duration of treatment limited to 12 months	No limitation on duration of treatment
Patients approaching the 12-month mark faced uncertainty about continuation	Ongoing treatment can continue without an administrative ceiling
Physicians managing longer-term patients had limited label support	Full prescribing information now covers two years of documented efficacy and safety
Every-other-month dosing option in year 2 not formally labeled	GATHER2 year-2 EOM data incorporated; flexible dosing schedules now supported by label

The label change also has implications for the roughly 210,000 vials of IZERVAY distributed through December 2024. Patients already on therapy who were managed month-to-month under the year-one framework can now continue with the support of two-year efficacy and safety data in the formal prescribing information.

Post-marketing safety reporting through the time of the label update remained consistent with the clinical trial program. No new or significant safety signals were identified in commercial use.

IZERVAY in Context: Two Approved Drugs for a Disease Once Left Untreated

The GA treatment landscape currently consists of two FDA-approved intravitreal complement inhibitors. No head-to-head clinical trial comparing them has been conducted. Here is a plain-language comparison of where they stand:

Feature	IZERVAY (avacincaptad pegol)	Syfovre (pegcetacoplan)
Developer	Astellas Pharma	Apellis Pharmaceuticals
Mechanism	Complement C5 inhibitor (RNA aptamer)	Complement C3 inhibitor (pegylated peptide)
Original FDA approval	August 2023	February 2023
Duration restriction	None, removed Feb 2025	None
Dosing	Monthly or every other month (EOM)	Monthly or every other month (EOM)
Pivotal trial primary endpoint (yr 1)	GATHER1: 27% reduction (2 mg); GATHER2: 14% reduction	OAKS: 21% reduction (monthly); DERBY: 12% reduction (not statistically significant)
Statistically significant primary endpoint	Met in both Phase 3 trials (GATHER1 and GATHER2)	Met in OAKS; not met in DERBY
Post-marketing retinal vasculitis signal	Not observed in clinical trials	Rare cases reported in post-marketing surveillance
Intraocular inflammation	No serious cases in GATHER2 through 2 years	Reported in post-marketing; retinal vasculitis cases
EU regulatory status	EMA application withdrawn by Astellas (Oct 2024)	Refused marketing authorization by EMA (Sep 2024)
Patient population studied	Non-center-point-involving GA only	Both subfoveal and non-subfoveal GA (broader population)

A few contextual points are worth understanding:

Neither drug has demonstrated improvement in best-corrected visual acuity (BCVA) in their pivotal trials, which is a genuine limitation and the source of ongoing debate in the retinal community. The EMA declined to approve both drugs on the grounds that lesion slowing without demonstrated functional benefit did not meet the European standard for clinical meaningfulness. The FDA, evaluating the same data, reached a different conclusion, accepting lesion growth rate as a valid surrogate endpoint for GA progression.

IZERVAY’s pivotal trials enrolled patients with non-center-point-involving GA, meaning GA that had not yet reached the central fovea. Syfovre’s trials enrolled a broader population including patients with subfoveal GA. This enrollment difference means the two trials are not directly comparable, and patients with subfoveal involvement are outside the population studied in GATHER1 and GATHER2.

No randomized head-to-head comparison has been conducted. The right drug for an individual patient involves shared decision-making with a retinal specialist considering both efficacy and safety, individual risk factors, and payer formulary.

Both drugs require indefinite monthly or bimonthly intravitreal injections, a significant treatment burden for an older patient population, many of whom have bilateral GA.

What This Means for Patients with Geographic Atrophy

The removal of the 12-month dosing limit is straightforward good news for patients already on IZERVAY who are tolerating the drug and want to continue. It is also good news for prescribers who can now manage GA patients on a longer-term basis with full label support and two years of documented efficacy and safety data.

What this approval does not change is the fundamental nature of GA treatment: these drugs slow the progression of an irreversible disease. They do not restore lost vision. The decision to start, continue, or stop treatment involves weighing modest lesion-growth benefit against the burden of indefinite injections, the small risk of wet AMD conversion, and the individual patient’s preferences, disease location, and visual function goals.

For patients with GA who have not yet been treated, the conversation with a retinal specialist should now include the full picture of two-year data, the flexibility of monthly or every-other-month dosing, and the comparative safety and efficacy profiles of the two available treatments.

The American Academy of Ophthalmology and the BrightFocus Foundation maintain current patient resources on geographic atrophy and AMD treatment options. For patients interested in clinical trials evaluating next-generation GA therapies, ClinicalTrials.gov lists open enrollment studies.

For related coverage of how FDA label updates are expanding treatment options across multiple specialties in 2026, see our post on Nexplanon’s FDA-approved extension from 3 years to 5 years and our analysis of the first approved immunotherapy for ovarian cancer.

Sources

Astellas press release: U.S. FDA Approves Expanded Label for IZERVAY (avacincaptad pegol intravitreal solution) for Geographic Atrophy. February 13, 2025. newsroom.astellas.com.

GATHER2 two-year results: Khanani AM et al. Avacincaptad pegol for geographic atrophy secondary to age-related macular degeneration: 2-year efficacy and safety results from the GATHER2 phase 3 trial. Ophthalmology. Published online December 15, 2025. doi:10.1016/S0161-6420(25)00790-0

GATHER1 Phase 2/3 results: Jaffe GJ et al. C5 Inhibitor Avacincaptad Pegol for Geographic Atrophy Due to Age-Related Macular Degeneration: A Randomized Pivotal Phase 2/3 Trial (GATHER1). Ophthalmology. 2021;128(4):576–586.

GATHER2 12-month results: Khanani AM et al. Efficacy and safety of avacincaptad pegol in patients with geographic atrophy (GATHER2): 12-month results from a randomised, double-masked, phase 3 trial. The Lancet. September 2023.

GATHER2 trial registration: NCT04435366. ClinicalTrials.gov.

GATHER1 trial registration: NCT02686658. ClinicalTrials.gov.

IZERVAY original FDA approval: FDA approves avacincaptad pegol for geographic atrophy secondary to age-related macular degeneration. FDA.gov. August 2023.

IZERVAY prescribing information: IZERVAY (avacincaptad pegol intravitreal solution). FDA.gov.

Ophthalmology Advisor label update coverage: Izervay Label Update Removes Limit on Treatment Duration for Geographic Atrophy. ophthalmologyadvisor.com. February 2025.

Applied Clinical Trials: Two Year Trial Data Show Long-Term Efficacy of Izervay. appliedclinicaltrialsonline.com.

AAO IZERVAY/Syfovre overview: What to Know About Syfovre and Izervay for Geographic Atrophy. aao.org. April 2025.

EMA Syfovre refusal: Syfovre: Final opinion confirming refusal of marketing authorisation. EMA. September 2024.

FDA Syfovre retinal vasculitis safety communication: FDA Drug Safety Communication: FDA warns about rare but serious risk of vision loss from retinal vasculitis associated with Syfovre. FDA.gov.

Patient resources: American Academy of Ophthalmology | BrightFocus Foundation | NEI AMD overview | ClinicalTrials.gov: geographic atrophy studies

Disclaimer: Health Evidence Digest provides general information about FDA approvals and health research for educational purposes. This content is not a substitute for professional medical advice. Treatment decisions regarding IZERVAY or any other geographic atrophy therapy should be made in consultation with a qualified, board-certified ophthalmologist or retinal specialist who can evaluate individual disease characteristics, risk factors, and treatment goals.

April 30, 2026